false --12-31 Q3 0001812727 0001812727 2026-01-01 2026-09-30 0001812727 XGPU:CommonStockParValue0.086PerShareMember 2026-01-01 2026-09-30 0001812727 XGPU:PreferredStockPurchaseRightsMember 2026-01-01 2026-09-30 0001812727 2026-11-16 0001812727 2026-09-30 0001812727 2025-12-31 0001812727 us-gaap:NonrelatedPartyMember 2026-09-30 0001812727 us-gaap:NonrelatedPartyMember 2025-12-31 0001812727 us-gaap:RelatedPartyMember 2026-09-30 0001812727 us-gaap:RelatedPartyMember 2025-12-31 0001812727 2026-07-01 2026-09-30 0001812727 2025-07-01 2025-09-30 0001812727 2025-01-01 2025-09-30 0001812727 us-gaap:NonrelatedPartyMember 2026-07-01 2026-09-30 0001812727 us-gaap:NonrelatedPartyMember 2025-07-01 2025-09-30 0001812727 us-gaap:NonrelatedPartyMember 2026-01-01 2026-09-30 0001812727 us-gaap:NonrelatedPartyMember 2025-01-01 2025-09-30 0001812727 us-gaap:RelatedPartyMember 2026-07-01 2026-09-30 0001812727 us-gaap:RelatedPartyMember 2025-07-01 2025-09-30 0001812727 us-gaap:RelatedPartyMember 2026-01-01 2026-09-30 0001812727 us-gaap:RelatedPartyMember 2025-01-01 2025-09-30 0001812727 us-gaap:CommonStockMember 2025-12-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001812727 us-gaap:RetainedEarningsMember 2025-12-31 0001812727 us-gaap:ParentMember 2025-12-31 0001812727 us-gaap:NoncontrollingInterestMember 2025-12-31 0001812727 us-gaap:CommonStockMember 2026-03-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001812727 us-gaap:RetainedEarningsMember 2026-03-31 0001812727 us-gaap:ParentMember 2026-03-31 0001812727 us-gaap:NoncontrollingInterestMember 2026-03-31 0001812727 2026-03-31 0001812727 us-gaap:CommonStockMember 2026-06-30 0001812727 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001812727 us-gaap:RetainedEarningsMember 2026-06-30 0001812727 us-gaap:ParentMember 2026-06-30 0001812727 us-gaap:NoncontrollingInterestMember 2026-06-30 0001812727 2026-06-30 0001812727 us-gaap:CommonStockMember 2024-12-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001812727 us-gaap:RetainedEarningsMember 2024-12-31 0001812727 us-gaap:ParentMember 2024-12-31 0001812727 us-gaap:NoncontrollingInterestMember 2024-12-31 0001812727 2024-12-31 0001812727 us-gaap:CommonStockMember 2025-03-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001812727 us-gaap:RetainedEarningsMember 2025-03-31 0001812727 us-gaap:ParentMember 2025-03-31 0001812727 us-gaap:NoncontrollingInterestMember 2025-03-31 0001812727 2025-03-31 0001812727 us-gaap:CommonStockMember 2025-06-30 0001812727 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001812727 us-gaap:RetainedEarningsMember 2025-06-30 0001812727 us-gaap:ParentMember 2025-06-30 0001812727 us-gaap:NoncontrollingInterestMember 2025-06-30 0001812727 2025-06-30 0001812727 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001812727 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001812727 us-gaap:ParentMember 2026-01-01 2026-03-31 0001812727 us-gaap:NoncontrollingInterestMember 2026-01-01 2026-03-31 0001812727 2026-01-01 2026-03-31 0001812727 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001812727 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001812727 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001812727 us-gaap:ParentMember 2026-04-01 2026-06-30 0001812727 us-gaap:NoncontrollingInterestMember 2026-04-01 2026-06-30 0001812727 2026-04-01 2026-06-30 0001812727 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001812727 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001812727 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001812727 us-gaap:ParentMember 2026-07-01 2026-09-30 0001812727 us-gaap:NoncontrollingInterestMember 2026-07-01 2026-09-30 0001812727 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001812727 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001812727 us-gaap:ParentMember 2025-01-01 2025-03-31 0001812727 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0001812727 2025-01-01 2025-03-31 0001812727 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001812727 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001812727 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001812727 us-gaap:ParentMember 2025-04-01 2025-06-30 0001812727 us-gaap:NoncontrollingInterestMember 2025-04-01 2025-06-30 0001812727 2025-04-01 2025-06-30 0001812727 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001812727 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001812727 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001812727 us-gaap:ParentMember 2025-07-01 2025-09-30 0001812727 us-gaap:NoncontrollingInterestMember 2025-07-01 2025-09-30 0001812727 us-gaap:CommonStockMember 2026-09-30 0001812727 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001812727 us-gaap:RetainedEarningsMember 2026-09-30 0001812727 us-gaap:ParentMember 2026-09-30 0001812727 us-gaap:NoncontrollingInterestMember 2026-09-30 0001812727 us-gaap:CommonStockMember 2025-09-30 0001812727 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001812727 us-gaap:RetainedEarningsMember 2025-09-30 0001812727 us-gaap:ParentMember 2025-09-30 0001812727 us-gaap:NoncontrollingInterestMember 2025-09-30 0001812727 2025-09-30 0001812727 XGPU:MedicalMember 2026-07-01 2026-09-30 0001812727 XGPU:LifeMember 2026-07-01 2026-09-30 0001812727 XGPU:PropertyAndCasualtyMember 2026-07-01 2026-09-30 0001812727 XGPU:MedicalMember 2025-07-01 2025-09-30 0001812727 XGPU:LifeMember 2025-07-01 2025-09-30 0001812727 XGPU:PropertyAndCasualtyMember 2025-07-01 2025-09-30 0001812727 XGPU:MedicalMember 2026-01-01 2026-09-30 0001812727 XGPU:LifeMember 2026-01-01 2026-09-30 0001812727 XGPU:PropertyAndCasualtyMember 2026-01-01 2026-09-30 0001812727 XGPU:MedicalMember 2025-01-01 2025-09-30 0001812727 XGPU:LifeMember 2025-01-01 2025-09-30 0001812727 XGPU:PropertyAndCasualtyMember 2025-01-01 2025-09-30 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember XGPU:PriorityHealthMember 2026-07-01 2026-09-30 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember XGPU:PriorityHealthMember 2025-07-01 2025-09-30 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember XGPU:BlueCrossBlueShieldMember 2026-07-01 2026-09-30 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember XGPU:BlueCrossBlueShieldMember 2025-07-01 2025-09-30 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember XGPU:ProgressiveMember 2026-07-01 2026-09-30 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember XGPU:PriorityHealthMember 2026-01-01 2026-09-30 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember XGPU:PriorityHealthMember 2025-01-01 2025-09-30 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember XGPU:BlueCrossBlueShieldMember 2026-01-01 2026-09-30 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember XGPU:BlueCrossBlueShieldMember 2025-01-01 2025-09-30 0001812727 XGPU:EnquantumLtdMember us-gaap:BridgeLoanMember 2026-01-31 0001812727 XGPU:SharePurchaseAgreementMember XGPU:EnquantumLtdMember 2026-02-05 0001812727 XGPU:EnquantumLtdMember 2026-01-01 2026-09-30 0001812727 XGPU:EnquantumLtdMember 2026-09-30 0001812727 XGPU:LifeSciGlobalGroupLLCMember 2026-04-30 0001812727 XGPU:LifeSciGlobalGroupLLCMember XGPU:LifeSciManagementGroupLLCMember 2026-04-30 0001812727 XGPU:LifeSciGlobalGroupLLCMember XGPU:LGGNoteMember 2026-04-30 0001812727 XGPU:LifeSciGlobalGroupLLCMember XGPU:LGGNoteMember 2026-04-30 2026-04-30 0001812727 XGPU:LifeSciGlobalGroupLLCMember XGPU:LGGNoteMember 2026-09-30 0001812727 XGPU:InnervateRadiopharmaceuticalsLLCMember XGPU:SubscriptionAgreementMember 2026-04-30 0001812727 XGPU:SubscriptionAgreementMember XGPU:InnervateRadiopharmaceuticalsLLCMember 2026-09-30 2026-09-30 0001812727 XGPU:InnervateRadiopharmaceuticalsLLCMember XGPU:SubscriptionAgreementMember 2026-09-30 0001812727 XGPU:SubscriptionAgreementMember XGPU:InnervateRadiopharmaceuticalsLLCMember srt:ScenarioForecastMember 2026-10-01 2026-12-31 0001812727 us-gaap:SubsequentEventMember XGPU:InnervateRadiopharmaceuticalsLLCMember XGPU:SubscriptionAgreementMember 2026-10-31 0001812727 XGPU:SubscriptionAgreementMember XGPU:InnervateRadiopharmaceuticalsLLCMember us-gaap:SubsequentEventMember 2026-10-01 0001812727 us-gaap:TrademarksAndTradeNamesMember 2026-09-30 0001812727 XGPU:InternallyDevelopedSoftwareMember 2026-09-30 0001812727 us-gaap:CustomerRelationshipsMember 2026-09-30 0001812727 us-gaap:TrademarksAndTradeNamesMember 2025-12-31 0001812727 XGPU:InternallyDevelopedSoftwareMember 2025-12-31 0001812727 us-gaap:CustomerRelationshipsMember 2025-12-31 0001812727 us-gaap:NoncompeteAgreementsMember 2025-12-31 0001812727 XGPU:ZECMember 2025-12-31 0001812727 2025-01-01 2025-12-31 0001812727 XGPU:BarraMember 2025-12-31 0001812727 2026-05-18 2026-05-18 0001812727 us-gaap:CommonStockMember XGPU:ATMAgreementMember 2026-01-01 2026-03-31 0001812727 us-gaap:CommonStockMember XGPU:PompensationProgramsMember 2026-04-01 2026-06-30 0001812727 us-gaap:LineOfCreditMember 2026-04-01 2026-06-30 0001812727 us-gaap:CommonStockMember XGPU:ATMAgreementMember 2026-04-01 2026-06-30 0001812727 us-gaap:CommonStockMember XGPU:PompensationProgramsMember 2026-07-01 2026-09-30 0001812727 us-gaap:CommonStockMember XGPU:ATMAgreementMember 2026-07-01 2026-09-30 0001812727 us-gaap:LineOfCreditMember 2026-07-01 2026-09-30 0001812727 srt:ExecutiveOfficerMember XGPU:EmploymentAgreementMember 2025-04-30 0001812727 srt:ExecutiveOfficerMember XGPU:EmploymentAgreementMember 2025-04-01 2025-04-30 0001812727 srt:ExecutiveOfficerMember XGPU:EmploymentAgreementMember 2026-07-01 2026-09-30 0001812727 srt:ExecutiveOfficerMember XGPU:EmploymentAgreementMember 2026-01-01 2026-09-30 0001812727 XGPU:EmploymentAgreementMember srt:ExecutiveOfficerMember 2026-09-30 0001812727 srt:ChiefExecutiveOfficerMember 2026-06-30 0001812727 srt:ChiefExecutiveOfficerMember 2026-06-30 2026-06-30 0001812727 srt:ChiefExecutiveOfficerMember 2026-07-01 2026-09-30 0001812727 srt:ChiefExecutiveOfficerMember 2026-01-01 2026-09-30 0001812727 srt:ChiefExecutiveOfficerMember 2026-09-30 0001812727 XGPU:ChiefTechnologyOfficerMember 2026-09-30 0001812727 XGPU:EquityBasedCommissionCompensationProgramMember 2026-07-01 2026-09-30 0001812727 XGPU:EquityBasedCommissionCompensationProgramMember 2026-01-01 2026-09-30 0001812727 XGPU:EquityIncentivePlanMember 2026-05-06 0001812727 XGPU:EquityIncentivePlanMember srt:MinimumMember 2026-05-06 0001812727 XGPU:EquityIncentivePlanMember srt:MaximumMember 2026-05-06 0001812727 XGPU:EquityIncentivePlanMember 2026-06-24 2026-06-24 0001812727 XGPU:EquityIncentivePlanMember 2026-06-24 0001812727 XGPU:EquityIncentivePlanMember 2026-07-01 2026-09-30 0001812727 XGPU:TwoThousandAndTwentyFiveEquityIncentivePlanMember 2026-09-30 0001812727 XGPU:AtTheMarketOfferingProgramMember 2026-07-01 2026-09-30 0001812727 XGPU:AtTheMarketOfferingProgramMember 2026-01-01 2026-09-30 0001812727 us-gaap:CommonStockMember 2026-01-29 2026-01-29 0001812727 XGPU:PrefundedWarrantsMember 2026-01-29 2026-01-29 0001812727 us-gaap:WarrantMember 2026-01-29 2026-01-29 0001812727 2026-01-29 0001812727 us-gaap:PrivatePlacementMember us-gaap:WarrantMember 2026-01-29 2026-01-29 0001812727 2026-01-28 2026-01-29 0001812727 us-gaap:PrivatePlacementMember us-gaap:WarrantMember 2026-01-29 0001812727 XGPU:PrefundedWarrantsMember 2026-01-01 2026-09-30 0001812727 us-gaap:WarrantMember 2026-01-01 2026-09-30 0001812727 us-gaap:WarrantMember 2026-09-30 0001812727 XGPU:PrefundedWarrantsMember 2026-09-30 0001812727 XGPU:PurchaseAgreementMember 2026-03-12 2026-03-12 0001812727 XGPU:PurchaseAgreementMember 2026-07-01 2026-09-30 0001812727 XGPU:PurchaseAgreementMember 2026-01-01 2026-09-30 0001812727 XGPU:PurchaseAgreementMember 2026-09-30 0001812727 2026-09-03 2026-09-03 0001812727 XGPU:StockholderRightsPlanMember 2026-09-03 0001812727 XGPU:SeriesAWarrantsMember 2026-01-01 2026-09-30 0001812727 XGPU:SeriesAWarrantsMember 2025-01-01 2025-09-30 0001812727 XGPU:PAWMember 2026-01-01 2026-09-30 0001812727 XGPU:PAWMember 2025-01-01 2025-09-30 0001812727 XGPU:PAWarrantsMember 2026-01-01 2026-09-30 0001812727 XGPU:PAWarrantsMember 2025-01-01 2025-09-30 0001812727 XGPU:SeriesJWarrantsMember 2026-01-01 2026-09-30 0001812727 XGPU:SeriesJWarrantsMember 2025-01-01 2025-09-30 0001812727 XGPU:SeriesJPAWMember 2026-01-01 2026-09-30 0001812727 XGPU:SeriesJPAWMember 2025-01-01 2025-09-30 0001812727 XGPU:SeriesKWarrantsMember 2026-01-01 2026-09-30 0001812727 XGPU:SeriesKWarrantsMember 2025-01-01 2025-09-30 0001812727 XGPU:SeriesKPAWMember 2026-01-01 2026-09-30 0001812727 XGPU:SeriesKPAWMember 2025-01-01 2025-09-30 0001812727 XGPU:UnvestedStockAwardsMember 2026-01-01 2026-09-30 0001812727 XGPU:UnvestedStockAwardsMember 2025-01-01 2025-09-30 0001812727 2026-09-17 2026-09-17 0001812727 us-gaap:RevolvingCreditFacilityMember XGPU:CreditAgreementMember 2025-03-05 0001812727 XGPU:SettlementAgreementMember 2026-03-31 0001812727 XGPU:SettlementAgreementMember 2026-03-13 0001812727 XGPU:SettlementAgreementMember 2026-03-11 0001812727 XGPU:InsuranceMember XGPU:CommissionIncomeMember 2026-07-01 2026-09-30 0001812727 XGPU:InsuranceMember XGPU:CommissionIncomeMember 2025-07-01 2025-09-30 0001812727 XGPU:InsuranceMember 2026-07-01 2026-09-30 0001812727 XGPU:InsuranceMember 2025-07-01 2025-09-30 0001812727 XGPU:InsuranceMember us-gaap:NonrelatedPartyMember 2026-07-01 2026-09-30 0001812727 XGPU:InsuranceMember us-gaap:NonrelatedPartyMember 2025-07-01 2025-09-30 0001812727 XGPU:InsuranceMember us-gaap:RelatedPartyMember 2026-07-01 2026-09-30 0001812727 XGPU:InsuranceMember us-gaap:RelatedPartyMember 2025-07-01 2025-09-30 0001812727 XGPU:InsuranceMember XGPU:CommissionIncomeMember 2026-01-01 2026-09-30 0001812727 XGPU:InsuranceMember XGPU:CommissionIncomeMember 2025-01-01 2025-09-30 0001812727 XGPU:InsuranceMember 2026-01-01 2026-09-30 0001812727 XGPU:InsuranceMember 2025-01-01 2025-09-30 0001812727 XGPU:InsuranceMember us-gaap:NonrelatedPartyMember 2026-01-01 2026-09-30 0001812727 XGPU:InsuranceMember us-gaap:NonrelatedPartyMember 2025-01-01 2025-09-30 0001812727 XGPU:InsuranceMember us-gaap:RelatedPartyMember 2026-01-01 2026-09-30 0001812727 XGPU:InsuranceMember us-gaap:RelatedPartyMember 2025-01-01 2025-09-30 0001812727 XGPU:TotalInsuranceSegmentRevenueMember 2026-07-01 2026-09-30 0001812727 XGPU:TotalInsuranceSegmentRevenueMember 2025-07-01 2025-09-30 0001812727 XGPU:TotalInsuranceSegmentRevenueMember 2026-01-01 2026-09-30 0001812727 XGPU:TotalInsuranceSegmentRevenueMember 2025-01-01 2025-09-30 0001812727 XGPU:AltruisBenefitConsultantsIncMember 2026-09-01 2026-09-30 0001812727 XGPU:AltruisBenefitConsultantsIncMember 2026-07-01 2026-09-30 0001812727 XGPU:AltruisBenefitConsultantsIncMember 2026-01-01 2026-09-30 0001812727 XGPU:SouthwesternMontanaInsuranceCenterMember 2026-09-01 2026-09-02 0001812727 XGPU:SouthwesternMontanaInsuranceCenterMember 2026-07-01 2026-09-30 0001812727 XGPU:SouthwesternMontanaInsuranceCenterMember 2026-01-01 2026-09-30 0001812727 XGPU:SouthwesternMontanaInsuranceCenterMember 2026-09-01 2026-09-30 0001812727 XGPU:AltruisBenefitConsultantsIncMember srt:ScenarioForecastMember 2027-08-27 0001812727 XGPU:AltruisBenefitConsultantsIncMember 2025-07-01 2025-09-30 0001812727 XGPU:AltruisBenefitConsultantsIncMember 2025-01-01 2025-09-30 0001812727 XGPU:SouthwesternMontanaInsuranceCenterMember 2025-07-01 2025-09-30 0001812727 XGPU:SouthwesternMontanaInsuranceCenterMember 2025-01-01 2025-09-30 0001812727 us-gaap:SubsequentEventMember XGPU:UISAgencyLLCMember 2026-10-13 0001812727 us-gaap:SubsequentEventMember XGPU:UISAgencyLLCMember 2026-10-13 2026-10-13 0001812727 XGPU:UISAgencyLLCMember 2026-07-01 2026-09-30 0001812727 XGPU:UISAgencyLLCMember 2025-07-01 2025-09-30 0001812727 XGPU:UISAgencyLLCMember 2026-01-01 2026-09-30 0001812727 XGPU:UISAgencyLLCMember 2025-01-01 2025-09-30 0001812727 us-gaap:SubsequentEventMember XGPU:UISAgencyLLCMember 2026-10-13 0001812727 us-gaap:SubsequentEventMember XGPU:UISAgencyLLCMember 2026-10-13 2026-10-13 0001812727 us-gaap:SubsequentEventMember XGPU:GPUExchangeCorpMember 2026-11-03 2026-11-03 0001812727 us-gaap:SubsequentEventMember XGPU:GPUExchangeCorpMember 2026-11-03 0001812727 us-gaap:SubsequentEventMember XGPU:GPUExchangeCorpMember XGPU:ConsultingAgreementMember 2026-11-03 0001812727 us-gaap:SubsequentEventMember XGPU:GPUExchangeCorpMember XGPU:ConsultingAgreementMember 2026-11-03 2026-11-03 0001812727 us-gaap:SubsequentEventMember XGPU:JudahKormanMember 2026-10-19 2026-10-19 0001812727 us-gaap:SubsequentEventMember XGPU:MordyBeymanMember 2026-10-19 2026-10-19 0001812727 us-gaap:SubsequentEventMember XGPU:EzraBeymanMember 2026-10-19 2026-10-19 0001812727 2026-06-24 2026-06-24 0001812727 XGPU:EzraBeymanMember us-gaap:SubsequentEventMember XGPU:TwoThousandTwentyFiveEquityIncentivePlanMember 2026-10-19 2026-10-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure XGPU:Segments

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____ to _____

 

Commission File Number: 001-40020

 

RELIANCE GLOBAL GROUP, INC.

(Exact name of registrant as specified in its charter)

 

Florida   46-3390293

(State or other jurisdiction

of incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

300 Blvd. of the Americas, Suite 105 Lakewood, NJ 08701

(Address of principal executive offices) (Zip Code)

 

732-380-4600

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.086 per share   XGPU   The Nasdaq Capital Market

Preferred Stock Purchase Rights

  N/A  

The Nasdaq Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company, in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
Emerging growth company ☐  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

 

Yes ☐ No ☒

 

At November 16, 2026, the registrant had 1,765,366 shares of common stock, par value $0.086 per share, outstanding.

 

 

 

 
 

 

TABLE OF CONTENTS

 

PART I  
Item 1. Condensed Consolidated Financial Statements (Unaudited) 3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. 20
Item 3. Quantitative and Qualitative Disclosures About Market Risk. 32
Item 4. Controls and Procedures. 32
PART II  
Item 1. Legal Proceedings. 33
Item 1A. Risk Factors. 33
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 39
Item 3. Defaults Upon Senior Securities. 39
Item 4. Mine Safety Disclosures. 39
Item 5. Other Information. 39
Item 6. Exhibits 40

 

2
 

 

Item 1. Condensed Consolidated Financial Statements (Unaudited)

 

Reliance Global Group, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(Unaudited)

 

   September 30 2026   December 31 2025 
Assets          
Current assets:          
Cash  $6,699,796   $1,315,634 
Restricted cash   -    1,415,725 
Accounts receivable   246,720    746,275 
Accounts receivable, related parties   1,681    3,530 
Other receivables   535,025    23,526 
Prepaid expense and other current assets   584,494    766,985 
Assets held for sale   

373,490

    

-

 
Total current assets   8,441,206    4,271,675 
           
Property and equipment, net   23,330    77,196 
Right-of-use assets   471,443    897,610 
Equity Investments   950,000    - 
Intangibles, net   2,191,099    3,387,980 
Goodwill   2,136,214    4,786,555 
Digital assets, fair value   -    108,913 
Other non-current assets   18,492    18,492 
Total assets  $14,231,784   $13,548,421 
           
Current liabilities:          
Accounts payable and other accrued liabilities  $996,214   $653,293 

Accounts payable and other accrued liabilities, related parties

   115,426      
Short term financing agreements   100,394    58,942 
Current portion of loans payables, related parties   -    286,546 
Other payables   155,291    83,263 
Current portion of long-term debt   -    1,038,294 
Operating lease liability, current portion   202,769    276,470 
Total current liabilities   1,570,094    2,396,808 
           
Long term debt, less current portion   -    4,062,972 
Operating lease liability, less current portion   303,352    661,211 
Total liabilities   1,873,446    7,120,991 
Stockholders’ equity          
Preferred stock, $0.086 par value; 750,000,000 shares authorized and 0 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively   -     - 
Common stock, $0.086 par value; 50,000,000 shares authorized and 1,683,409 and 266,103 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively   144,773    22,885 
Additional paid-in capital   67,399,440    61,465,850 
Accumulated deficit   (55,176,405)   (55,061,305)
Total Reliance Global Group, Inc. stockholders’ equity   12,367,808    6,427,430 
Noncontrolling interest   (9,470)   - 
Total stockholders’ equity   12,358,338    6,427,430 
Total liabilities and stockholders’ equity  $14,231,784   $13,548,421 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

3
 

 

Reliance Global Group, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(Unaudited)

 

                     
   Three Months Ended   Nine Months Ended 
   September 30, 2026   September 30, 2025   September 30, 2026   September 30, 2025 
Revenue                    
Commission income  $ 1,842,997    2,495,975   $ 7,780,604    9,818,872 
Total revenue    1,842,997    2,495,975     7,780,604    9,818,872 
                       
Operating expenses                      
Commission expense    783,707    995,945     3,192,515    3,454,147 
Salaries and wages    3,262,869    3,912,326     6,443,020    8,705,682 
General and administrative expenses    948,630    1,120,776     3,462,860    4,129,842 
Marketing and advertising expenses    21,870    66,917     362,888    201,399 
Depreciation and amortization    216,829    313,694     774,249    1,020,440 
Asset impairments    90,841    -      90,841    -  
Total operating expenses    5,324,746    6,409,658     14,326,373    17,511,510 
                       
Loss from operations    (3,481,749)   (3,913,683)    (6,545,769)   (7,692,638)
                       
Other income (expense)                      
Interest expense    (127,399)   (246,722)    (378,444)   (844,846)
Interest expense related parties    -    (4,704)    -    (50,811)
Other income (expense), net    51,630    (16,470)    12,363    (41,068)
Loss from Equity Method Investment    -    -     (120,384)   -  
Equity investments impairment loss    (713,771)   -     (713,771)   -  
Gain on sale of business    7,730,012    3,033,554     7,730,012    3,033,554 
Loss on Extinguishment of debt    (117,841)   -     (117,841)   -  
Unrealized gains (losses) on digital assets, net    -    (8,558)    9,263    (8,558)
Total other income    6,822,631    2,757,100     6,421,198    2,088,271 
                       
Net income (loss)  $ 3,340,881    (1,156,583)  $ (124,571)    (5,604,367)
                       
Less: Net loss attributable to non-controlling interests    (6,557)   -     (9,470)   - 
Net income (loss) attributable to Reliance Global Group, Inc.    3,347,438    (1,156,583)    (115,101)    (5,604,367)
Basic earnings (loss) per share                      
Basic earnings (loss) per share  $ 2.39  $(7.94)  $ (0.30)  $(57.61)
                       
Diluted earnings (loss) per share                      
Diluted earnings (loss) per share  $ 2.34  $(7.94)  $ (0.30)  $(57.61)
                       
Weighted average number of shares outstanding – Basic    1,402,845    145,675     816,360    97,279 
                       
Weighted average number of shares outstanding – Diluted    1,429,665    145,675     816,360    97,279 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

4
 

 

Reliance Global Group, Inc. and Subsidiaries

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

 

                              
   Common Stock  

Additional

Paid-in

   Accumulated  

Total Reliance

Global Group, Inc.

Stockholders’

   Non Controlling   Total 
   Shares   Amount   Capital   Deficit   Equity   Interest   Equity 
                             
Balance December 31, 2025 (Audited)   266,103   $22,885   $61,465,850   $(55,061,305)  $6,427,430    -   $6,427,430 
                                    
Common share-based compensation   250    22    15,478    -    15,500    -    15,500 
                                    
Common shares issued for ATM share sales   2,241    194    33,886    -    34,080    -    34,080 
                                    
Common shares and warrants issued for a public offering   262,732    22,595    2,521,530    -    2,544,125    -    2,544,125 
                                    
Deemed dividend   -         (130,910)   -     (130,910)   -    (130,910)
                                    
Net loss   -    -    -    (1,471,167)   (1,471,167)   -    (1,471,167)
                                    
Balance, March 31, 2026   531,325    45,696    63,905,834    (56,532,472)   7,419,058    -    7,419,058 
                                    
Common share-based compensation   250    21    15,597    -     15,618    -    15,618 
                                    
Additional Public Offering costs   -    -    (17,825)   -     (17,825)   -    (17,825)
                                    
Common shares issued for reverse stock split round up   480    41    (41)   -     -    -    - 
                                    
Common shares issued for services   9,156    787    129,956    -     130,743    -    130,743 
                                    
Common shares issued pursuant to sales on an Equity Line of Credit   3,000    258    11,109    -     11,367    -    11,367 
                                    
Common shares issued for ATM share sales   276,737    23,799    1,058,774    -     1,082,573    -    1,082,573 
                                    
Net loss   -     -     -     (1,991,371)   (1,991,371)   (2,913)   (1,994,284)
                                    
Balance, June 30, 2026   820,948    70,602    65,103,404    (58,523,843)   6,650,163    (2,913)   6,647,250 
                                    
Common share-based compensation   350,361    30,128    976,162    -     1,006,290    -     1,006,290 
                                    
Common shares issued for services   24,916    2,144    57,860    -     60,004    -     60,004 
                                    
Common shares issued for ATM share sales   235,518    20,256    574,594    -     594,850    -     594,850 
                                    
Common shares issued pursuant to sales on an Equity Line of Credit   251,666    21,643    687,420    -     709,063    -     709,063 
                                    
Net Income   -     -    -     3,347,438    3,347,438    (6,557)   3,340,881 
                                    
Balance, September 30, 2026   1,683,409   $144,773   $67,399,440   $(55,176,405)  $12,367,808   $(9,470)  $12,358,338 

 

5
 

 

   Common Stock  

Additional

Paid-in

   Accumulated  

Total Reliance

Global Group, Inc.

Stockholders’

   Noncontrolling     
   Shares   Amount   Capital   Deficit   Equity   Interest   Total 
Balance December 31, 2024 (Audited)   56,255   $4,838   $51,065,953   $(48,073,549)  $        2,997,242   $                   -   $2,997,242 
                                    
Common share-based compensation   11,566    995    973,990    -    974,985    -    974,985 
                                    
Common shares issued for services   2,625    226    141,524    -    141,750    -    141,750 
                                    
Common shares issued for acquisition purchase price prepayment   3,925    338    239,087    -    239,425    -    239,425 
                                    
Net loss   -   $-   $-   $(1,736,882)  $(1,736,882)  $-   $(1,736,882)
                                    
Balance, March 31, 2025   74,372   $6,397   $52,420,554   $(49,810,431)  $2,616,520   $-   $2,616,520 
                                    
Common share-based compensation   1   $-   $877,368   $-   $877,368   $-   $877,368 
                                    
Common shares issued for services   3,099    267    149,733    -    150,000    -    150,000 
                                    
Common shares issued for private placement   -    -    2,148,631    -    2,148,631    -    2,148,631 
                                    
Net loss   -         -    (2,710,901)   (2,710,901)   -    (2,710,901)
                                    
Balance, June 30, 2025   77,472   $6,664   $55,596,286   $(52,521,332)  $3,081,618   $-   $3,081,618 
                                    
Common share-based compensation   59,714   $5,135   $2,735,661   $-   $2,740,796   $-   $2,740,796 
                                    
Common shares issued for services   2,767    238    92,412    -    92,650    -    92,650 
                                    
Common shares issued for private placement   37,202    3,199    (15,304)   -    (12,105)   -    (12,105)
                                    
Common shares issued for ATM share sales   44,643    3,839    2,017,843   $-    2,021,682    -    2,021,682 
                                    
Common shares issued pursuant to sales on an Equity Line of Credit   12,580    1,082    348,918    -    350,000    -    350,000 
                                    
Dividend payable   -    -    (373,986)   -    (373,986)   -    (373,986)
                                    
Net loss   -    -     -    (1,156,583)   (1,156,583)   -    (1,156,583)
                                    
Balance, September 30, 2025   234,378   $20,157   $60,401,830   $(53,677,915)  $6,744,072   $-   $6,744,072 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

6
 

 

Reliance Global Group, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

         
   Nine Months Ended September 30, 
   2026   2025 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss  $(124,571)  $(5,604,367)
Adjustment to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   774,249    1,020,440 
Asset impairments   

90,841

    - 
Amortization of debt issuance costs and accretion of debt discount   16,069    94,631 
Non-cash lease expense   1,077   5,040 
Equity based compensation expense   1,151,969    4,593,149 
Equity based payments to third parties   439,114    719,839 
Gain on sale of business   (7,730,012)   (3,033,554)
Loss on equity method investment   120,384    - 
Equity investments impairment loss   713,771    - 
Loss on Extinguishment of debt   117,841    - 
Unrealized (gains) losses on digital assets, net   (9,263)   8,558 
Change in operating assets and liabilities:          
Accounts receivable   213,439    596,335 
Accounts receivable, related parties   1,849    3,180 
Other receivables   (61,531)   (46,306)
Prepaid expense and other current assets   (71,052)   (112,125)
Other non-current assets   -    1,500 
Accounts payables and other accrued liabilities   431,503    224,927 
Other payables   72,028    59,626 
Net cash used in operating activities   (3,852,295)   (1,469,127)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchase of property and equipment   (8,417)   (15,901)
Purchase of intangibles   (15,196)   (26,788)
Sale of business   10,163,271    4,447,069 
Payments for Purchases of Crypto Assets   -    (114,960)
Proceeds from Sales of Crypto Assets   118,176    - 
Investment in equity investments   (1,784,155)   - 
Net cash provided by investing activities   8,473,679    4,289,420 
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Principal repayments of debt   (5,235,176)   (5,913,713)
Proceeds from short term financings   150,947    192,360 
Principal repayments of short-term financings   (109,505)   (144,783)
Proceeds from loans payable, related parties   -    1,142,166 
Payments of loans payable, related parties   (286,536)   (898,808)
Proceeds from common shares issued through an at the market offering   1,711,503    2,021,682 
Proceeds from common shares issued through a public offering   2,526,300    - 
Proceeds from common shares issued through an Equity Line of Credit   720,430    350,000 
Series J Private Placement   -    2,136,526 
Cash paid for deemed dividends   (130,910)   - 
Net cash used in financing activities   (652,947)   (1,114,570)
           
Net increase in cash and restricted cash   3,968,437    1,705,723 
Cash and restricted cash at beginning of period   2,731,359    1,797,694 
Cash and restricted cash at end of period  $6,699,796   $3,503,417 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

7
 

 

Reliance Global Group, Inc. and Subsidiaries

Notes to the Unaudited Condensed Consolidated Financial Statements

 

NOTE 1. SUMMARY OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES

 

Reliance Global Group, Inc., formerly known as Ethos Media Network, Inc. (“RELI”, “Reliance”, or the “Company”), was incorporated in Florida on August 2, 2013.

 

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions for Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of recurring accruals) necessary for a fair presentation have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto, set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 (the “Form 10-K”), as the same may be amended from time to time. Capitalized terms not defined in this Quarterly Report on Form 10-Q refer to capitalized terms as defined in the Form 10-K. Certain prior period accounts and balances in these unaudited condensed consolidated financial statements and notes thereto may have been reclassified to conform to the current period’s presentation.

 

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned and majority owned subsidiaries. During the second quarter of 2026, the Company formed LifeSci Global Group LLC (“LGG”), of which the Company owns 51% through its wholly owned subsidiary EZRA International Group, LLC (“EIG”). LGG is consolidated as a majority-owned subsidiary, and the equity interest not attributable to the Company is presented as a noncontrolling interest. All intercompany transactions and balances have been eliminated in consolidation. Current and long-lived assets forming the disposal group of UIS Agency, LLC (UIS), have been reclassified and separately presented on the September 30, 2026, condensed consolidated balance sheet, as current assets held for sale. No liabilities were classified as related to assets held for sale. See Note 13 – Assets Held for Sale.

 

Liquidity

 

As of September 30, 2026, the Company’s reported cash balance was $6,699,796, current assets were approximately $8,441,000 and current liabilities were approximately $1,570,000. As of September 30, 2026, the Company had working capital of approximately $6,871,000 and stockholders’ equity of approximately $12,358,000. For the nine months ended September 30, 2026, the Company had a loss from operations of approximately $6,546,000 and net loss of approximately $125,000.

 

Although there can be no assurance that debt or equity financing will be available on acceptable terms, or at all, the Company believes its financial position and its ability to raise capital to be reasonable and sufficient. Based on our assessment, we do not believe there are conditions or events that, in the aggregate, raise substantial doubt about the Company’s ability to continue as a going concern within one year of filing these unaudited financial statements with the Securities and Exchange Commission (“SEC”).

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.

 

Cash and Restricted Cash

 

Cash and restricted cash (restricted for debt service coverage) on our unaudited condensed consolidated statements of cash flows consists of the following:

 

   September 30, 2026   September 30, 2025 
Cash  $6,699,796   $2,581,219 
Restricted cash   -    922,198 
Total cash and restricted cash  $6,699,796   $3,503,417 

 

8
 

 

Equity Investments

 

Equity investments in entities over which the Company does not exercise control or significant influence, and for which there is no readily determinable fair value, are accounted for under the measurement alternative in ASC 321, Investments—Equity Securities. Under this alternative, such investments are carried at cost, less impairment, and adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. The Company evaluates such investments for impairment at each reporting period based on qualitative and quantitative factors, including the investee’s financial condition, operating results, and near-term business prospects.

 

Equity Method Investments

 

The Company accounts for investments in entities over which it exercises significant influence but does not control using the equity method of accounting (ASC 323). Under the equity method, the investment is initially recorded at cost and subsequently adjusted for the Company’s proportionate share of the investee’s net income or loss, which is presented as a non-operating item in the Company’s unaudited condensed consolidated statements of operations. Dividends received reduce the carrying value of the investment. The Company performs a memo purchase price allocation at the date of each investment to identify basis differences between the cost allocated to the investee’s assets and liabilities and the investee’s carrying values of those assets and liabilities. Indefinite-lived basis differences are not amortized until the related activities are complete or abandoned; definite-lived basis differences are amortized over the useful life of the underlying asset. The Company assesses its equity method investments for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. The Company translates the financial statements of its equity method investee whose functional currency is not the U.S. dollar using the current rate method; resulting translation adjustments when material are recorded in other comprehensive income. As of September 30, 2026, the Company had no investments accounted for under the equity method.

 

Revenue Recognition

 

The following table disaggregates the Company’s revenue by line of business, showing commissions earned:

 

Period Ended September 30, 2026  Medical   Life   Property and Casualty   Total 
                 
Three months ended September 30, 2026  $1,065,881   $32,885   $744,231   $1,842,997 
Three months ended September 30, 2025  $1,774,019   $30,590   $691,366   $2,495,975 
Nine Months ended September 30, 2026  $5,409,068   $64,523   $2,307,013   $7,780,604 
Nine Months ended September 30, 2025  $7,248,223   $95,320   $2,475,329   $9,818,872 

 

The following are customers representing 10% or more of total revenue:

 

   Three Months Ended September 30, 
Insurance Carrier  2026   2025 
Priority Health   36%   29%
BlueCross BlueShield   16%   25%
Progressive   11%   - 

 

   Nine Months Ended September 30, 
Insurance Carrier  2026   2025 
Priority Health   39%   31%
BlueCross BlueShield   15%   17%

 

No other single customer accounted for more than 10% of the Company’s commission revenues during the three and nine months ended September 30, 2026 and 2025. The loss of any significant customer could have a material adverse effect on the Company.

 

Income Taxes

 

The Company recorded no income tax expense for the three and nine months ended September 30, 2026 and 2025 because the estimated annual effective tax rate was zero. In determining the estimated annual effective income tax rate, the Company analyzes various factors, including projections of the Company’s annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, the ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives.

 

9
 

 

As of September 30, 2026 and December 31, 2025, the Company provided a full valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.

 

Noncontrolling Interests

 

Noncontrolling interests represent the portion of equity in a consolidated subsidiary that is not attributable, directly or indirectly, to the Company. Noncontrolling interests are presented as a separate component of stockholders’ equity in the unaudited condensed consolidated balance sheets. Net income or loss is attributed to the Company and to the noncontrolling interest in proportion to their respective ownership interests, and losses are attributed to the noncontrolling interest even if doing so results in a deficit noncontrolling interest balance.

 

Recently Issued Accounting Pronouncements

 

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. In January 2025, the FASB issued ASU 2025-01 to clarify its effective date. The amendments require additional disclosures about specified expense categories within income statement captions, including employee compensation, depreciation and amortization, as applicable, as well as disclosures about selling expenses. The guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently assessing the impact of this guidance on its consolidated financial statements and related disclosures.

 

In July 2025, the FASB issued ASU 2025-05, Measurement of Credit Losses for Accounts Receivable and Contract Assets, which simplifies certain aspects of applying ASC 326, Financial Instruments—Credit Losses, to current accounts receivable and contract assets arising from transactions accounted for under ASC 606, Revenue from Contracts with Customers. The ASU permits entities to apply a practical expedient when estimating expected credit losses for certain short-term receivables and contract assets. The Company adopted ASU 2025-05 during the quarter ended June 30, 2026. The adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements or related disclosures.

 

In September 2025, the FASB issued ASU 2025-06, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. The amendments remove references to prescribed software development stages and revise the criteria for determining when internal-use software costs qualify for capitalization. The guidance is effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is permitted as of the beginning of an annual reporting period. The Company is currently assessing the impact of this guidance on its consolidated financial statements and related disclosures.

 

In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. The amendments clarify the applicability of interim reporting guidance, improve the organization of interim disclosure requirements and establish a principle requiring disclosure of events since the end of the most recent annual reporting period that have a material impact on the entity. For public business entities, the guidance is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently assessing the impact of this guidance on its consolidated financial statements and related disclosures.

 

Except as discussed above and in the Company’s most recent Annual Report on Form 10-K, the Company does not expect other recently issued accounting pronouncements to have a material impact on its consolidated financial statements or related disclosures.

 

NOTE 2. Equity Investments

 

Investment In Enquantum

 

In January 2026, the Company advanced a $166,000 secured bridge loan to Enquantum Ltd. (“Enquantum”), an Israeli quantum encryption technology company. The bridge loan converted into equity on February 19, 2026 in connection with the initial closing under a Share Purchase Agreement (“SPA”) entered into on February 5, 2026, pursuant to which the Company may acquire up to 51% of Enquantum’s fully diluted ordinary shares for aggregate consideration of approximately $2.1 million payable in milestone-based tranches. As of September 30, 2026, the Company had funded an aggregate of $834,155 including the converted bridge loan, and held 85,088 ordinary shares of Enquantum, representing approximately 34% of Enquantum’s issued and outstanding shares. The Company has no obligation to fund any remaining amounts under the SPA, and no liability has been recorded for the unfunded portion as of September 30, 2026.

 

The Company previously accounted for its investment under the equity method pursuant to ASC 323 based on its ability to exercise significant influence over Enquantum’s financial and operating policies, including through its board representation. The Company recognized equity method losses of $120,384 for the nine months ended September 30, 2026, recorded within loss from equity method investment in the Company’s unaudited condensed consolidated statements of operations. No additional equity method losses were recognized during the three months ended September 30, 2026.

 

During the third quarter of 2026, Enquantum experienced significant operational and governance changes, and the Company determined that it no longer had the ability to exercise significant influence over Enquantum and discontinued equity method accounting. The Company subsequently accounted for its retained investment under the measurement alternative in ASC 321, at cost less impairment, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer.

 

10
 

 
Based on Enquantum’s cessation of operations, financial condition, lack of committed funding and limited recovery prospects for its technology and intellectual property, the Company recognized an impairment loss of $713,771 for the three and nine months ended September 30, 2026, reducing the investment to its estimated fair value of zero. The loss was recorded within equity investments impairment loss in the Company’s unaudited condensed consolidated statements of operations and included all remaining equity method basis differences related to intellectual property and in-process research and development. The Company retains its ownership interest in Enquantum and continues to evaluate its rights and remedies under the SPA. 

 

Formation of LGG and Investment in Innervate

 

In April 2026, the Company formed LifeSci Global Group LLC, a Delaware limited liability company, to pursue investments in healthcare and life sciences companies. The Company holds approximately 51% of LGG’s membership interests through its wholly owned subsidiary EZRA International Group, LLC, and LifeSci Management Group LLC (“Management Group”), an entity owned by certain members of the Company’s management and Board of Directors, holds the remaining approximately 49%. LGG is consolidated as a majority-owned subsidiary of the Company, and the interest held by Management Group is presented as a noncontrolling interest in the unaudited condensed consolidated financial statements.

 

In connection with the formation of LGG, EIG entered into a promissory note with LGG (the “LGG Note”) providing for advances of up to $2.0 million to fund LGG’s investment activities. The LGG Note bears interest at 7% per annum, compounded annually, and matures on April 29, 2031. As of September 30, 2026, $950,000 had been advanced under the LGG Note. The LGG Note and the related interest eliminate in consolidation and had no effect on consolidated net loss; however, the interest expense recognized at the LGG level is reflected in the allocation of net loss to the noncontrolling interest.

 

On April 30, 2026, LGG entered into a subscription agreement to acquire a minority equity interest in Innervate Radiopharmaceuticals LLC (“Innervate”), an early-stage life sciences company developing radiopharmaceutical product candidates, for aggregate consideration of up to approximately $2.0 million, payable in tranches. As of September 30, 2026, LGG had funded $950,000 and held 200,000 units of Innervate, representing an ownership interest of approximately 1.05% on an as-issued basis. Subsequent to September 30, 2026, LGG funded additional installments totaling $225,000 in the fourth quarter of 2026, increasing its holdings to 247,368 units. Funding of the remaining installments is at LGG’s discretion, and no liability has been recorded for the unfunded portion, which was approximately $1.1 million as of September 30, 2026.

 

The Company, through LGG, does not exercise control or significant influence over Innervate, and there is no readily determinable fair value for the investment. Accordingly, the investment is accounted for as an equity investment under the measurement alternative in ASC 321, Investments—Equity Securities, and is carried at cost, less impairment, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. As of September 30, 2026, there were no impairment losses or observable price adjustments that needed to be recognized, and the carrying value of the investment was $950,000 presented within equity investments in the unaudited condensed consolidated balance sheets.

 

In connection with the investment, LGG receives warrants to purchase additional units of Innervate at a ratio of one warrant for every two units purchased, at an exercise price of $4.75 per unit and exercisable through October 31, 2029. As of September 30, 2026, LGG had acquired 100,000 warrants in connection with the units funded, and an additional 15,789 warrants in connection with the units funded subsequent to September 30, 2026. LGG is also entitled to certain preferential payment rights providing for a return of its subscription price prior to ordinary distributions to other members of Innervate. No value has been separately ascribed to the warrants or preferential payment rights as of September 30, 2026.

 

The formation of LGG, the LGG Note, and the investment in Innervate constitute related party transactions. Certain members of the Company’s management and Board of Directors hold ownership interests in Management Group, and one member of the Company’s Board of Directors serves as the chief executive officer of Innervate. These transactions were reviewed and approved by the independent and disinterested members of the Company’s Board of Directors.

 

11
 

 

NOTE 3. INTANGIBLE ASSETS AND GOODWILL

 

Intangible Assets

 

The following table sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of September 30, 2026:

 

  

Weighted

Average

Remaining

Amortization

Period

(Years)

 

Gross

Carrying

Amount

  

Accumulated

Amortization

  

Net Carrying

Amount

 
Trade name and trademarks  1.6  $720,328   $(716,548)  $3,780 
Internally developed software  1.6   1,775,800    (1,565,898)   209,902 
Customer relationships  5.3   3,686,000    (1,708,583)   1,977,417 
Total     $6,182,128   $(3,991,029)  $2,191,099 

 

The following table sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of December 31, 2025:

 

  

Weighted

Average

Remaining

Amortization

period

(Years)

 

Gross

Carrying

Amount

  

Accumulated

Amortization

  

Net Carrying

Amount

 
Trade name and trademarks  0.3  $1,479,027   $(1,427,398)  $51,629 
Internally developed software  1.3   1,760,605    (1,305,944)   454,661 
Customer relationships  4.2   5,384,560    (2,557,337)   2,827,223 
Non-competition agreements  0.3   2,661,150    (2,606,683)   54,467 
Total     $11,285,342   $(7,897,362)  $3,387,980 

 

The following table reflects expected amortization expense as of September 30, 2026, for each of the following five years and thereafter:

 

Years Ending December 31, 

Amortization

Expense

 
2026  $161,130 
2027   470,393 
2028   391,245 
2029   382,105 
2030   373,344 
Thereafter   412,882 
Total  $2,191,099 

 

Goodwill

 

During the third quarter of 2026, the Company derecognized approximately $1.9 million and $0.4 million of goodwill in connection with the sale of substantially all the operating assets of Altruis Benefit Consultants, Inc. and the sale of Southwestern Montana Insurance Center, LLC, respectively. See Note 12 — Divestitures. The Company also reclassified approximately $373,000 of goodwill to assets held for sale in connection with the sale of UIS (see Note 13 — Assets Held for Sale).

 

The changes in the carrying amount of goodwill for the nine months ended September 30, 2026 were as follows:

Balance at December 31, 2025  $4,786,555 
Goodwill derecognized upon divestitures   (2,276,851)
Goodwill reclassified to assets held for sale   (373,490)
Balance at September 30, 2026  $2,136,214 

 

NOTE 4. DIGITAL ASSETS

 

The Company did not hold any digital assets as of September 30, 2026. The following table summarizes the Company’s digital asset holdings as of December 31, 2025:

 

Digital Asset  Holdings   Cost Basis   Fair Value   Hierarchy 
                 
ZEC   213.140310   $117,811   $108,913    Level 1 

 

12
 

 

NOTE 5. LONG-TERM DEBT AND SHORT-TERM FINANCINGS

 

Long-Term Debt

 

During the three months ended September 30, 2026, the Company fully repaid its outstanding term loan with Oak Street Funding LLC, which was originally entered into in connection with the acquisition of Barra & Associates, LLC. As a result, no amounts remained outstanding under the loan as of September 30, 2026. In connection with the repayment, the Company recognized a loss on extinguishment of debt of $117,841 primarily related to the write-off of remaining unamortized deferred financing costs.

 

As of December 31, 2025, the Company’s long-term debt consisted of the following:

   December 31, 2025 
     
Oak Street Funding LLC Term Loan for the acquisition of Barra & Associates, LLC, variable interest of prime rate plus 2.5%, net of deferred financing costs of $133,909 as of December 31, 2025, respectively   5,101,266 
Less: current portion   (1,038,294)
Long-term debt  $4,062,972 

 

Short-Term Financings

 

The Company has various short-term notes payable for financed items such as insurance premiums. These are normally paid in equal installments over a period of twelve months or less and carry interest rates of up to 11.25% per annum. As of September 30, 2026, and December 31, 2025, balances outstanding on short-term financings were approximately $100,000 and $59,000 respectively.

 

NOTE 6. EQUITY

 

Common Stock

 

The Company is authorized to issue 50,000,000 shares of common stock, $0.086 par value (the “Common Stock”). Each share of issued and outstanding common stock entitles the holder thereof to fully participate in all shareholder meetings, to cast one vote on each matter with respect to which shareholders have the right to vote, and to share ratably in all dividends and other distributions declared and paid with respect to common stock, as well as in the net assets of the Company upon liquidation or dissolution.

 

On May 18, 2026, the Company effectuated a 1-for-40 reverse stock split of the Company’s issued and outstanding common stock (the “Reverse Split-2026”). The par value remained unchanged following the Reverse Split-2026. All share and per share information as well as common stock and additional paid-in capital have been retrospectively adjusted to reflect the Reverse Split-2026 for all periods presented, unless otherwise indicated. The Reverse Split-2026 resulted in a rounding addition of approximately 480 shares valued at par.

 

During the first quarter of 2026, the Company issued 250 shares of Common Stock with a value of $15,500 for equity-based compensation under certain disclosed (see Equity-based Compensation) equity-based compensation programs, 2,241 shares of common stock shares with a net value of $34,080 through its ATM Program, and 262,732 shares of common stock with a net value of $2,544,125 in the Series K Public Offering of common shares and warrants.

 

13
 

 

During the second quarter of 2026, the Company issued 250 shares of Common Stock with a value of $15,618 for equity-based compensation under certain disclosed equity-based compensation programs, 480 shares of common stock with a value of $0 in connection with the rounding of fractional shares resulting from the reverse stock split, 9,156 shares of common stock with a value of $130,743 for services rendered, 3,000 shares of common stock with a value of $11,367 under its Equity Line of Credit, and 276,737 shares of common stock with a value of $1,082,573 through its ATM Program. Additionally, the Company recorded a charge of $17,825 to additional paid-in capital related to second quarter offering costs associated with the Series K Public Offering of common shares and warrants.

 

During the third quarter of 2026, the Company issued 350,361 shares of Common Stock with a value of $1,006,290 for equity-based compensation under certain disclosed equity-based compensation programs, 24,916 shares of common stock with a value of $60,004 for services rendered, 235,518 shares of common stock with a net value of $594,850 through its ATM Program, and 251,666 shares of common stock with a value of $709,063 under its Equity Line of Credit.

 

As of September 30, 2026, and December 31, 2025, there were 1,683,409 and 266,103 shares of common stock outstanding, respectively.

 

Equity-based Compensation

 

Pursuant to the April 2025 second amendment to an employment agreement between the Company and an executive, the executive was awarded 1,000 shares of the Company’s Common Stock annually over the four-year employment term, with each annual tranche vesting equally at 250 shares per quarter, pro-rated for any partial periods. The total fair value of the award is approximately $248,000. During the three and nine months ended September 30, 2026, 250 and 750 shares were issued pursuant to the award. As of September 30, 2026, unrecognized compensation expense related to the award was approximately $159,000 which is expected to be recognized through June 2029. For the three and nine month periods ended, September 30, 2026, compensation expense on this grant was $15,500 and $46,500, respectively.

 

In June 2026, the Compensation Committee approved annual equity awards for the Company’s Chief Executive Officer, Chief Operating Officer, Chief Technology Officer and a Vice President with aggregate grant-date values of $1,808,000, payable in shares of Common Stock under the 2025 Plan, with the number of shares determined by reference to the closing price on the applicable grant date. Because each award represents a fixed monetary amount settled in a variable number of shares, the awards are classified as liabilities. Compensation cost is recognized ratably over the twelve-month compensation period to which each award relates, or upon delivery of shares or payment of cash, if earlier. Awards with a value of $624,768 were settled through the June 2026 Grant. For the three and nine months ended September 30, 2026, the Company recognized compensation expense of $739,445 related to these awards, including the $624,768 settled in shares, and an accrued liability of $114,677 is included in accounts payable and other accrued liabilities, related parties, as of September 30, 2026. As of September 30, 2026, unrecognized compensation cost related to these awards was approximately $1,069,000. Approximately $761,000 of that amount was recognized in October 2026 upon the cash settlement described in Note 14, and the remainder is expected to be recognized through June 2027. The Chief Technology Officer’s award of $300,000 and $94,308 of the Chief Executive Officer’s award remain payable in shares, subject to the availability of shares under the 2025 Plan

 

Pursuant to an equity-based commission compensation program at one of the Company’s subsidiaries which provided down-line agents the ability to earn and receive restricted stock awards upon completion of agreed upon service requirements, the Company granted annual restricted stock awards which have vesting or other restrictions of up to twelve months. For the three and nine month period ended September 30, 2026, approximately 64,180 shares were issued under the program, all fully vested as of September 30, 2026.

 

Total stock-based compensation expense recorded in the unaudited condensed consolidated statements of operations for the three months ended September 30, 2026, and 2025 was $1,120,969 and $2,740,796, respectively, and for the nine months ended September 30, 2026 and 2025; $1,151,969 and $4,593,149, respectively.

 

2025 Equity Incentive Plan

 

On May 6, 2026, the Company’s stockholders approved an amendment to the Company’s 2025 Equity Incentive Plan (the “2025 Plan”) to increase the number of shares of common stock authorized for issuance under the 2025 Plan by 350,000 shares, from 50,000 shares to 400,000 shares. The amendment was approved at the Company’s 2026 Annual Meeting of Stockholders.

 

On June 24, 2026, the Compensation Committee approved awards of 285,931 restricted shares of Common Stock under the 2025 Plan (the “June 2026 Grant”) to certain directors, officers and employees, with a grant-date fair value of $987,892 based on the closing price of $3.455 per share. The shares were originally scheduled to vest in installments between July 1, 2026 and September 15, 2026. On July 27, 2026, the Compensation Committee accelerated the vesting of all then-unvested shares to that date. The acceleration did not result in incremental compensation cost, and the remaining unrecognized cost was recognized upon acceleration. As of September 30, 2026, all 285,931 shares had vested and been issued, and compensation expense of $987,892 was recognized during the three months ended September 30, 2026.

 

Following the June 2026 Grant, and after giving effect to the reverse stock split effective May 18, 2026, there remained 1,792 shares available for issuance under the Company’s 2025 Equity Incentive Plan.

 

At-the-Market Offering Program

 

During the three and nine months ended September 30, 2026, the Company sold 235,518 and 514,496 shares of Common Stock, respectively, under the ATM Program for net proceeds of approximately $594,850 and $1,711,503, respectively. As of September 30, 2026, the ATM Program has been substantially fully utilized and approximately $184 of Common Stock remained available for issuance under the ATM Program.

 

Series K Public Offering

 

On January 29, 2026, the Company closed a registered public offering (the “Series K Public Offering”) of 185,185 shares of its common stock, which included 4,704 pre-funded warrants issued in lieu of common stock (the “Series K PF Warrants”), together with warrants to purchase up to 370,370 shares of common stock (the “Series K Warrants”), at a combined public offering price of $10.80 per share (or $10.76 per Series K PF Warrant). Each share of common stock (or Series K PF Warrant) was issued together with two Series K Warrants, each exercisable for one share of common stock at an exercise price of $10.80 per share and expiring two years from the initial exercise date. The Series K Warrants and Series K PF Warrants were classified as equity instruments. The Series K Public Offering generated gross proceeds of approximately $2.0 million, before deducting placement agent fees and other offering expenses. The Company intends to use the net proceeds from the Series K Public Offering for working capital, merger and acquisition activities, and general corporate purposes.

 

14
 

 

In connection with the Series K Public Offering, the Company agreed to pay the placement agent a cash fee equal to 7.0% of the gross proceeds, a management fee equal to 1.0% of the gross proceeds, and reimbursement of certain expenses. In addition, the Company issued 12,963 placement agent warrants (the “Series K PAWs”), representing 7.0% of the aggregate number of shares of common stock and Series K PF Warrants sold in the offering. The Series K PAWs have an exercise price of $13.50 per share and expire two years from the initial exercise date.

 

During the nine months ended September 30, 2026, all 4,704 Series K PF Warrants were exercised, and 77,546 Series K Warrants were exercised for aggregate proceeds of approximately $837,500. As of September 30, 2026, 292,824 Series K Warrants and 12,963 Series K PAWs remained outstanding.

 

Equity Line of Credit (ELOC)

 

On March 12, 2026, the Company entered into Amendment No. 2 to the Common Stock Purchase Agreement with White Lion Capital, LLC (the “ELOC Agreement”). The amendment extends the term of the facility by modifying the definition of the “Commitment Period” to continue through the earlier of (i) the date on which the investor has purchased shares equal to the full commitment amount under the ELOC Agreement or (ii) December 31, 2028. In addition, the amendment increased the total committed capital available to the Company under the ELOC Agreement (the “Commitment Amount”) to $50,000,000. During the three and nine months ended September 30, 2026, the Company sold 251,666 and 254,666 shares, respectively, under the ELOC Agreement for net proceeds of approximately $709,000 and $720,000. As of September 30, 2026, remaining capacity under the facility was approximately $48.3 million. 

 

On May 6, 2026, the Company’s stockholders approved the issuance of shares of the Company’s common stock in excess of the Exchange Cap under Nasdaq Listing Rule 5635(d) pursuant to the ELOC Agreement. The approval provides the Company with additional flexibility to issue shares under the facility, subject to the terms and conditions of the ELOC Agreement.

 

Stockholder Rights Plan

 

On September 3, 2026, the Company adopted a one-year stockholder rights plan and entered into a Rights Agreement with VStock Transfer, LLC, as rights agent. Under the plan, stockholders of record as of September 18, 2026 received one preferred stock purchase right for each outstanding share of common stock. Each right entitles the holder to purchase one one-thousandth of a share of Series A Preferred Stock at an exercise price of $14.00, subject to adjustment. The rights generally become exercisable if a person or group acquires 15% or more of the Company’s outstanding common stock without Board approval, subject to certain exceptions, including a 20% threshold for certain passive institutional investors. The rights expire on September 3, 2027, unless earlier redeemed, exchanged or terminated in accordance with the agreement. The Rights have no voting or dividend privileges until exercised and had no standalone fair value upon issuance; accordingly, the adoption of the Rights Agreement had no impact on the Company’s condensed consolidated financial statements as of and for the three and nine months ended September 30, 2026. In accordance with ASC 260, Earnings Per Share, because the Rights are contingently issuable and the triggering conditions had not been met as of September 30, 2026, the Rights were excluded from the computation of diluted earnings (loss) per share for the three and nine months ended September 30, 2026.

 

NOTE 7. EARNINGS (LOSS) PER SHARE

 

Basic earnings per common share (“EPS”) applicable to common stockholders is computed by dividing earnings applicable to common stockholders by the weighted-average number of common shares outstanding.

 

Diluted EPS includes the effect of potentially dilutive securities, except when their inclusion would be antidilutive.

 

The following table sets forth the computation of basic and diluted net income (loss) per common share:

 

    Three Months Ended     Three Months Ended  
    September 30, 2026     September 30, 2025  
Net income (loss) attributable to Reliance Global Group, Inc.   $ 3,347,438     $ (1,156,583 )
Less: deemed dividend adjustment     -       -  
Net income (loss), numerator, basic computation     3,347,438       (1,156,583 )
Net income (loss), numerator, dilutive computation   $ 3,347,438     $ (1,156,583 )
                 
Weighted average common shares, basic     1,402,845       145,675  
Effect of dilutive stock based awards    

26,820

      -  
Weighted average common shares, dilutive    

1,429,665

      145,675  
Earnings (loss) per common share – basic   $ 2.39     $ (7.94 )
Earnings (loss) per common share – diluted   $ 2.34     $ (7.94 )

 

    Nine Months Ended     Nine Months Ended  
    September 30, 2026     September 30, 2025  
Net loss attributable to Reliance Global Group, Inc.   $ (115,101 )    $ (5,604,367 )
Less: deemed dividend adjustment     (130,910 )      -  
Net loss, numerator, basic computation     (246,011 )      (5,604,367 )
Net loss, numerator, dilutive computation   $ (246,011 )    $ (5,604,367 )
                 
Weighted average common shares, basic     816,360       97,279  
Weighted average common shares, dilutive     816,360       97,279  
Loss per common share – basic   $ (0.30 )    $ (57.61 )
Loss per common share – diluted   $ (0.30 )    $ (57.61 )

 

15
 

 

Additionally, the following are considered anti-dilutive securities excluded from weighted-average shares used to calculate diluted net income (loss) per common share:

 

             
    As of September 30,  
    2026     2025  
Shares subject to outstanding Series A warrants     -       166  
Shares subject to outstanding PAW’s     24       24  
Shares subject to PA Warrants     77       77  
Shares subject to Outstanding Series J Warrants     74,405       74,405  
Shares subject to Outstanding Series J PAW’s     2,604       2,604  
Shares subject to outstanding Series K Warrants     292,824       -  
Shares subject to outstanding Series K PAWs     12,963       -  
Shares subject to unvested stock awards     2,569       17,253  

 

NOTE 8. LEASES

 

Operating lease expense for the three months ended September 30, 2026, and 2025 was $75,597 and $96,960, respectively. Operating lease expense for the nine months ended September 30, 2026, and 2025 was $248,889 and $313,322 respectively. As of September 30, 2026, the weighted average remaining lease term and weighted average discount rate for the operating leases were 2.66 years and 7.60%, respectively.

 

The following table depicts future minimum lease payments for the Company’s operating leases.

 

Fiscal year ending December 31, 

Operating Lease

Obligations

 
2026  $58,628 
2027   219,383 
2028   179,738 
2029   74,946 
2030   26,344 
Total undiscounted operating lease payments   559,039 
Less: Imputed interest   (52,918)
Present value of operating lease liabilities  $506,121 

 

NOTE 9. COMMITMENTS AND CONTINGENCIES

 

Legal Contingencies

 

The Company is subject to various legal proceedings and claims, either asserted or unasserted, arising in the ordinary course of business. While the outcome of these claims cannot be predicted with certainty, management does not believe the outcome of any of these matters will have a material adverse effect on our business, financial position, results of operations, or cash flows, and accordingly no legal contingencies are accrued as of September 30, 2026, and December 31, 2025. Litigation relating to the insurance brokerage industry is not uncommon. As such the Company, from time to time has been subject to such litigation. No assurances can be given with respect to the extent or outcome of any such litigation in the future.

 

Legal Settlement

 

On September 17, 2026, the Company and its subsidiary, Altruis Benefit Consultants, Inc., entered into a settlement and release agreement with certain third parties resolving an arbitration related to contractual and insurance commission disputes. Under the agreement, the Company was entitled to receive $70,000, which was recognized within other income (expense), net during the three and nine months ended September 30, 2026. The agreement also established the parties’ respective rights to certain ongoing insurance commissions and provided for mutual releases of claims.

 

NOTE 10. RELATED PARTY TRANSACTIONS

 

Americana Credit Agreement and Revolving Note

 

On March 5, 2025, the Company entered into a Revolving Credit Facility Agreement with YES Americana Group, LLC (“Americana”), which was amended on June 24, 2025 (the “Credit Agreement”). Under the Credit Agreement, Americana agreed to provide the Company with a revolving credit facility of up to $2,000,000 (the “Facility”). During the second quarter of 2026, the Company repaid all amounts outstanding under the Facility, and no borrowings remained outstanding as of September 30, 2026.

 

16
 

 

As of September 30, 2026, there were no outstanding loans payable to related parties, compared to $286,546 as of December 31, 2025. Interest expense on related party loans was $0 and $4,704 for the three months ended September 30, 2026 and 2025, respectively, and $0 and $50,811 for the nine months then ended.

 

Settlement Agreements

 

Reliance Global Holdings, LLC (“RGH”), an affiliate of the Company, was previously party to certain guarantees related to historical stock purchase transactions involving the Company’s common stock. In March 2026, the Company entered into two separate full and final release and settlement agreements (collectively, the “Settlement Agreements”) with third parties relating to such transactions and the related guarantees issued by RGH. Under the terms of the Settlement Agreements, the Company agreed to pay aggregate cash consideration of approximately $130,910, consisting of approximately $90,560 pursuant to a settlement agreement entered into on March 13, 2026, and approximately $40,350 pursuant to a settlement agreement entered into on March 11, 2026. Upon payment, the settlement amounts represented full and final satisfaction of all claims and obligations arising from the underlying stock purchase transactions and related guarantees, and the parties exchanged mutual releases. All prior obligations related to these matters were terminated. The Company’s independent directors approved the Settlement Agreements and related payments, determining that resolution of these matters was in the best interests of the Company.

 

Formation of LGG and Investment in Innervate

 

During the nine months ended September 30, 2026, the Company formed LGG and, through LGG, invested in Innervate. These transactions involve related parties, as certain members of the Company’s management and Board of Directors hold ownership interests in the noncontrolling member of LGG, and one member of the Company’s Board of Directors serves as the chief executive officer of Innervate. For a full description of these related party transactions, including the Company’s ownership interests, the intercompany promissory note, and the investment in Innervate, see Note 2 - Formation of LGG and Investment in Innervate.

 

Related Party Compensation Arrangements

 

Certain of the Company’s executive officers are immediate family members of the Chairman and Chief Executive Officer or of a member of the Board of Directors. These officers participated in the June 2026 Grant and, in the case of the Chief Operating Officer and a Vice President, the annual officer equity awards described in Note 6. Their compensation, including the cash settlement described in Note 14, was approved by the independent members of the Compensation Committee without the participation of any interested director.

 

NOTE 11. SEGMENT REPORTING

 

The Company’s Chief Executive Officer serves as the Chief Operating Decision Maker (“CODM”). The CODM evaluates the performance of the Company’s operations and makes decisions regarding the allocation of resources based on the operating results of the Company’s insurance business.

 

Following changes in its strategic focus and internal reporting, the Company began reporting a single reportable segment in the second quarter of 2026. Prior-period segment information has been recast to conform to the current-period presentation. Segment profit or loss is measured based on segment net income (loss), which reflects the operating results of the Company’s insurance business. Corporate overhead, depreciation and amortization, asset impairments, equity investments impairment loss, gain on sale, and loss on extinguishment of debt are excluded from the measure of segment profit or loss regularly reviewed by the CODM and are presented as reconciling items to consolidated results. Corporate overhead includes cash and non-cash executive compensation, public company costs, professional fees, SEC reporting costs, equity investment related costs, and other corporate expenses not included in the measure of segment profit or loss reviewed by the CODM.

 

The CODM regularly reviews commission revenue and the following significant expense categories in evaluating segment performance:

 

  ● Commission expense
  ● Salaries and wages
  ● General and administrative expenses
  ● Marketing and advertising
  ● Interest expense

 

The Company does not provide the CODM with information regarding segment assets, and accordingly, such information is not regularly reviewed for purposes of assessing performance or allocating resources.

 

17
 

 

The following tables present financial information for the Company’s reportable segment.

 

         
    Three Months Ended September 30,  
    2026     2025  
    Insurance     Insurance  
             
Commission income   $ 1,842,997     $ 2,495,975  
Total Revenue     1,842,997       2,495,975  
Total operating expenses                
Commission expense     783,707       995,945  
Salaries and wages     792,917       869,538  
General and administrative expenses     271,116       258,364  
Marketing and advertising     3,728       8,583  
Interest expense     119,693       240,491  
Interest (expense) related parties     -       4,491  
Segment net income/(loss)   $ (128,164 )   $ 118,563  

 

         
    Nine Months Ended September 30,  
    2026     2025  
    Insurance     Insurance  
             
Commission income   $ 7,780,604     $ 9,818,872  
Total Revenue     7,780,604       9,818,872  
Total operating expenses                
Commission expense     3,192,515       3,454,147  
Salaries and wages     2,327,956       3,228,657  
General and administrative expenses     796,665       970,902  
Marketing and advertising     10,583       42,574  
Interest expense     360,743       829,090  
Interest (expense) related parties     -       50,378  
Segment net income   $ 1,092,143     $ 1,243,124  

 

Reconciliation of total segment revenue and net income to consolidated results:

 

    Three Months Ended     Three Months Ended  
    September 30, 2026     September 30, 2025  
Total insurance segment revenue   $ 1,842,997     $ 2,495,975  
Consolidated revenue     1,842,997       2,495,975  
                 
Total insurance segment net income     (128,164 )     118,563  
Corporate overhead     (3,121,685 )     (3,995,007 )
Gain on sale of business     7,730,012       3,033,554  
Depreciation and amortization     (216,829 )     (313,694 )
Asset Impairments    

(90,841

)     -  

Equity investments impairment loss

   

(713,771

)     -  

Loss on Extinguishment of debt

   

(117,841

)     -  
Consolidated net income (loss)  $ 3,340,881     $ (1,156,583 )

 

    Nine Months Ended     Nine Months Ended  
    September 30, 2026     September 30, 2025  
Total segment revenue   $ 7,780,604     $ 9,818,872  
Consolidated revenue     7,780,604       9,818,872  
                 
Total segment net income     1,092,143       1,243,124  
Corporate overhead     (7,250,024 )     (8,860,605 )
Gain on sale of business     7,730,012       3,033,554  
Depreciation and amortization     (774,249 )     (1,020,440 )
Asset Impairments    

(90,841

)     -  
Equity investments impairment loss    

(713,771

)     -  

Loss on Extinguishment of debt

   

(117,841

)     -  
Consolidated net income (loss)   $ (124,571 )   $ (5,604,367 )

 

18
 

 

NOTE 12. DIVESTITURES

 

Sale of Altruis Benefit Consultants, Inc.

 

On September 24, 2026, the Company completed the sale of substantially all the operating assets of its wholly owned subsidiary, Altruis Benefit Consultants, Inc. (“Altruis”), to Altruis Benefit Management, LLC (the “Buyer”). The Buyer also assumed certain liabilities associated with the business. Altruis remains a wholly owned subsidiary of the Company.

 

The purchase price was $8.0 million, subject to a post-closing working capital adjustment, consisting of approximately $4.4 million in cash, a $3.1 million secured promissory note, a $300,000 indemnity holdback and a $161,729 working capital holdback. The promissory note was repaid in full on September 30, 2026. The indemnity holdback bears interest at 4% annually and is generally payable twelve months after closing, subject to indemnification claims. The Company may also receive contingent earnout payments of up to $1.0 million over three years based on specified revenue growth targets.

 

The Company recognized a gain on sale of approximately $5.8 million during the three and nine months ended September 30, 2026, which is presented as gain on sale of business within other income (expense) in the accompanying unaudited condensed consolidated statements of operations. No contingent earnout consideration was recognized as of September 30, 2026.

 

The pretax operating results attributable to Altruis, excluding the gain on sale, included in continuing operations were as follows:

 

   2026   2025   2026   2025 
   Three Months Ended September 30,   Nine Months Ended September 30, 
   2026   2025   2026   2025 
Pretax income (loss)  $10,564   $197,369   $1,161,663   $1,134,900 

 

Sale of Southwestern Montana Insurance Center

 

Effective September 1, 2026, the Company completed the sale of 100% of its ownership interests in Southwestern Montana Insurance Center, LLC (“SWM”) to Scali, LLC, for fixed consideration of $2,625,000, together with additional contingent consideration based on future operating performance.

 

Upon completion of the sale, the Company deconsolidated SWM and recognized a gain of $1,926,360, included within gain (loss) on sale of business within other income (expense) in the Company’s unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2026. Transaction-related legal fees of $47,500 were recognized separately within general and administrative expenses.

 

The agreement also provides for an uncapped cash earnout equal to 8.75 times the amount by which SWM’s EBITDA for the twelve months ending August 31, 2027 exceeds $300,000. As the contingency remained unresolved at September 30, 2026, no earnout receivable or additional gain was recognized under the Company’s ASC 450 gain-contingency accounting policy. Certain post-closing working-capital and other settlements remain subject to reconciliation.

 

The pretax operating results attributable to SWM, excluding the gain on sale, included in continuing operations were as follows:

 

   2026   2025   2026   2025 
   Three Months Ended September 30,   Nine Months Ended September 30, 
   2026   2025   2026   2025 
Pretax income (loss)  $(47,004)  $16,985   $(21,656)  $40,242 

 

NOTE 13. ASSETS HELD FOR SALE

 

During the third quarter of 2026, the Company committed to a plan to sell all membership interests in its wholly owned subsidiary UIS. The disposal group met the criteria for classification as held for sale under ASC 360 as of September 30, 2026. The disposal did not qualify as a discontinued operation under ASC 205-20 because it did not represent a strategic shift having a major effect on the Company’s operations and financial results.

 

The disposal group consisted of goodwill of $373,490, finite-lived intangible assets of $90,749 and property and equipment of $92. Retained cash and receivables are excluded from the disposal group and remain in their respective consolidated balance-sheet captions. Payables and accrued liabilities retained by the Company also remain in their regular consolidated liability captions. No liabilities were classified as related to assets held for sale.

 

The Company recognized an impairment loss of $90,841 for the three and nine months ended September 30, 2026, recorded within Asset Impairments in operating expenses. The impairment loss recognized under ASC 360 was limited to the aggregate carrying amount of the finite-lived intangible assets and property and equipment included in the disposal group; no goodwill impairment was recognized. Gross assets held for sale of $464,331, less a $90,841 valuation allowance, were presented as current assets held for sale of $373,490. Depreciation and amortization ceased upon classification as held for sale. No assets or liabilities were classified as held for sale at December 31, 2025.

 

On October 13, 2026, the Company completed the sale of all membership interests in UIS to Lorelei E. Saavedra-Ramirez for $120,000 in cash received on that date. Based on September 30 carrying amounts, the additional pre-tax loss on disposal is $253,490, subject to changes from Q4 accounting activity before the sale. The disposal loss is recognized in the fourth quarter of 2026.

 

UIS reported standalone pretax losses of approximately $118,000 and $31,268 for the three months ended September 30, 2026 and 2025, respectively. For the nine months ended September 30, 2026 and 2025, UIS reported standalone pretax losses of approximately $84,000 and $55,407, respectively.

 

NOTE 14. SUBSEQUENT EVENTS

 

Sale of UIS Agency, LLC

 

On October 13, 2026, the Company completed the sale of 100% of its ownership interests in UIS Agency, LLC (“UIS”), a wholly owned insurance brokerage subsidiary, to a third party for cash consideration of $120,000, pursuant to a Membership Interest Purchase Agreement. As the transaction occurred subsequent to September 30, 2026, no gain or loss on the sale was recognized in the accompanying unaudited condensed consolidated financial statements.

 

Acquisition of Oblivus

 

On November 3, 2026, the Company, through its wholly owned subsidiary GPU Exchange Corp., acquired the assets of Oblivus, a GPU cloud computing platform and marketplace, from Skyportal Inc. for $3,000,000 in cash plus up to $750,000 contingent upon specified cash-basis revenue milestones during the following twelve months. Of the contingent amount, $375,000 was deposited into escrow at closing. The Company entered into a twelve-month consulting agreement with Oblivus’s founder, Matthew Antoun, providing for $250,000 in cash and stock grants with an aggregate value of up to $600,000, subject to Board approval. The stock grants include $50,000 issuable within thirty days after closing, with the balance subject to stock price milestones. The agreement also provides for a bonus equal to 5% of gross profit received from qualifying introduced transactions. The Company also obtained a time-limited right, without obligation, to invest up to $500,000 in Skyportal under specified financing terms. The Company is evaluating the accounting for the transaction and related arrangements.

 

Cash Settlement of Certain Equity Awards

 

On October 19, 2026, the Compensation Committee of the Board of Directors approved cash payments, in lieu of shares, of $224,193.84 to Judah Korman (Chief Operating Officer), $124,730.13 to Mordy Beyman (Vice President) and $440,000.00 to Ezra Beyman (Chairman and Chief Executive Officer), in settlement of the unissued balances of equity awards approved on June 24, 2026 (aggregate cash of $788,923.97). The remaining $94,308.38 of Mr. Ezra Beyman’s award remains payable in shares, subject to share availability under the 2025 Equity Incentive Plan. Mr. Korman is the son of a director and Mr. Mordy Beyman is the son of the Chief Executive Officer.

 

19
 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q, as well as the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2025 (the “Annual Report”). Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks, uncertainties and assumptions. You should read the sections titled “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors” in this Quarterly Report on Form 10-Q and in our Annual Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this report—including statements regarding our strategy (including our digital-asset treasury strategy and related blockchain/tokenization initiatives), our acquisition of the Oblivus GPU cloud computing business and our plans to expand our GPU computing capacity and marketplace operations under the GPU Exchange brand, future financial condition, liquidity and capital resources, future operations, projected revenues, earnings (losses), margins, cash flows, business prospects, potential acquisitions and integration, and plans and objectives of management—are forward-looking statements.

 

Words such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “guidance,” “intends,” “may,” “might,” “outlook,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “should,” “targets,” “will,” “would,” and similar expressions (and negative forms of such words) are intended to identify forward-looking statements. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that may cause actual results to differ materially, including, but not limited to:

 

  ● our need to raise additional capital, which may not be available on acceptable terms or at all;
  ● our ability to satisfy and maintain compliance with The Nasdaq Capital Market’s continued listing standards, including the $1.00 minimum bid price requirement; and, if it becomes effective, the $5.0 million minimum Market Value of Listed Securities (“MVLS”) requirement;
  ● our ability to maintain the listing of our common stock on the Nasdaq Capital Market;
  ● volatility in the price of our securities due to changes in the capital markets, our industry, or our capital structure;
  ● our ability to execute on our acquisition strategy and integrate acquired businesses successfully;
  ● our ability to retain key personnel and effectively manage growth;
  ● the risk that we and our agency partners are unable to generate expected revenues or margins;
  ● risks associated with the insurance brokerage industry, including carrier concentration, regulation, competition, and cyclicality;
  ● the impact of economic conditions, inflation, and interest rate trends on our operations and customer demand;
  ● our ability to successfully integrate and operate the Oblivus GPU cloud computing business, a line of business in which we have limited operating experience and our ability to achieve the revenue and growth we expect from that business or obtain the capital required to expand our GPU capacity;
  ● risks associated with our recently announced expansion into the technology sector through our EZRA International Group platform and our Scale51 operating model, including our ability to identify, complete, and integrate investments in technology-driven businesses and the risk of further losses such as the loss of our investment in Enquantum;
  ● risks associated with our recent expansion into the life sciences sector through LifeSci Global Group LLC, including the speculative nature of early-stage life sciences investments including its investment in Innervate, and conflicts of interest with our directors and officers;
  ● potential disruptions due to cybersecurity incidents or system failures;
  ● risks associated with legal proceedings and compliance obligations;and
  ● other risks and uncertainties described in this Quarterly Report on Form 10-Q (including under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”) and in our other filings with the Securities and Exchange Commission.

 

Forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Except as required by applicable law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are expressly qualified in their entirety by this cautionary note.

 

20
 

 

Overview

 

Reliance Global Group, Inc. (the “Company”) is a diversified company engaged in insurance brokerage, InsurTech, and technology-related businesses. During the nine months ended September 30, 2026, the Company’s primary operations consisted of its insurance brokerage businesses and proprietary technology platforms, including RELI Exchange and 5MinuteInsure.com. Subsequent to September 30, 2026, the Company expanded into the GPU cloud computing and artificial intelligence infrastructure sector through its acquisition of Oblivus, as further described under Recent Developments. The Company intends to develop its GPU computing operations while continuing to operate its existing insurance and InsurTech businesses.

 

Recent Developments

 

Nasdaq Ticker Symbol Change and GPU Exchange Branding

 

On November 9, 2026, the Company announced that its ticker symbol on The Nasdaq Capital Market would change from “EZRA” to “XGPU,” effective at the open of trading on November 10, 2026. The ticker symbol change reflects the Company’s expansion into the GPU cloud computing and artificial intelligence (“AI”) infrastructure market following its acquisition of the assets of Oblivus on November 3, 2026.

 

In connection with this strategic expansion, the Company is adopting “GPU Exchange” as its doing-business-as name, and the acquired Oblivus business will operate under the GPU Exchange brand. The Company’s legal name will remain Reliance Global Group, Inc., and its common stock will continue to be listed on The Nasdaq Capital Market under the new ticker symbol, with no change to its CUSIP number.

 

The Company intends to focus on expanding its GPU computing capacity and marketplace operations while continuing to operate and develop its RELI Exchange InsurTech platform.

 

Acquisition of Oblivus

 

On November 3, 2026, the Company, through its wholly owned subsidiary GPU Exchange Corp., completed the acquisition of the assets of Oblivus, a GPU cloud computing platform and marketplace, from Skyportal Inc. for cash consideration of $3.0 million, plus up to an additional $750,000 contingent upon the achievement of specified revenue milestones over the following twelve months. Of the contingent consideration, $375,000 was deposited into escrow at closing.

 

In connection with the acquisition, the Company entered into a twelve-month consulting agreement with Oblivus’s founder, providing for cash compensation of $250,000 and potential stock awards valued at up to $600,000, subject to Board approval and certain conditions. The acquisition represents an expansion of the Company’s technology operations into the GPU cloud computing sector and supports its strategy of pursuing growth opportunities beyond its traditional insurance brokerage operations.

 

Cash Settlement of Certain Equity Awards

 

On October 19, 2026, our Compensation Committee approved cash payments totaling $788,923.97, in lieu of shares, in settlement of unissued balances of equity awards approved on June 24, 2026 for our Chairman and Chief Executive Officer, our Chief Operating Officer and a Vice President (two of whom are related to directors or officers). See Note 14 to the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for additional information.

 

Sale of UIS Agency LLC

 

On October 13, 2026, the Company completed the sale of 100% of its ownership interests in UIS Agency LLC (“UIS”), a wholly owned insurance brokerage subsidiary, for cash consideration of $120,000. As of September 30, 2026, the Company had classified the assets of UIS as held for sale and recognized an impairment loss of approximately $91,000 during the third quarter of 2026. The Company expects to recognize an additional loss upon completion of the sale in the fourth quarter of 2026, subject to final closing adjustments.

 

Business Operations

 

Repayment of Oak Street Funding Loan

 

During the third quarter of 2026, the Company fully repaid its outstanding term loan with Oak Street Funding LLC, which was originally entered into in connection with the acquisition of Barra & Associates, LLC. In connection with the repayment, the Company recognized a loss on extinguishment of debt of approximately $118,000, primarily related to the write-off of unamortized deferred financing costs. As of September 30, 2026, no amounts remained outstanding under the loan. The repayment reduced the Company’s outstanding indebtedness and future interest obligations.

 

Sale of Southwestern Montana Insurance Center

 

Effective September 1, 2026, the Company completed the sale of 100% of its ownership interests in Southwestern Montana Insurance Center, LLC (“SWM”) for consideration of approximately $2.6 million, together with additional contingent consideration based on future operating performance. In connection with the sale, the Company recognized a gain of approximately $1.9 million during the third quarter of 2026.

 

Sale of Altruis Benefit Consultants

 

In September 2026, the Company completed the sale of substantially all the operating assets of Altruis Benefit Consultants, Inc. (“Altruis”) for aggregate consideration of $8.0 million, subject to certain working capital adjustments and including cash consideration, a secured promissory note and certain holdbacks. The Company may also receive additional contingent consideration of up to $1.0 million based on future revenue growth. In connection with the sale, the Company recognized a gain of approximately $5.8 million during the third quarter of 2026.

 

Equity Investments

 

During the first quarter of 2026, the Company, through its Scale51 operating model, and EZRA International Group (“EIG”), pursued selected strategic equity investments in technology and healthcare-related businesses. During the second quarter of 2026, management reassessed its strategic priorities and capital allocation objectives and reduced its level of Scale51 activity while selectively evaluating future investment opportunities.

 

Enquantum

 

The Company invested approximately $0.8 million in Enquantum Ltd., a cybersecurity company, during 2026. Following Enquantum’s cessation of operations during the third quarter, and considering its financial condition, lack of committed funding and limited recovery prospects, the Company recognized a non-cash impairment charge of approximately $0.7 million, reducing the investment’s carrying value to zero. Including approximately $0.1 million of equity method losses recognized earlier in the year, total investment-related losses were approximately $0.8 million for the nine months ended September 30, 2026. The Company retains its ownership interest, has no obligation to fund additional amounts under the Share Purchase Agreement and continues to evaluate its rights and remedies under that agreement.

 

LGG and Investment in Innervate

 

In April 2026, the Company formed LifeSci Global Group LLC (“LGG”) as a platform for healthcare and life sciences investments. The Company owns approximately 51% of LGG through its wholly owned subsidiary EZRA International Group, LLC (“EIG”). The remaining interest is held by an entity affiliated with certain members of management and the Board of Directors. LGG entered into an agreement to invest up to approximately $2.0 million in Innervate Radiopharmaceuticals LLC (“Innervate”), an early-stage life sciences company, with funding payable in installments at LGG’s discretion. As of September 30, 2026, LGG had invested $0.95 million and held an approximately 1.05% ownership interest in Innervate. Subsequent to quarter-end, LGG invested approximately an additional $0.23 million, bringing its aggregate investment to approximately $1.18 million. A Company director serves as Innervate’s chief executive officer. The related-party arrangements were reviewed and approved by the independent and disinterested members of the Company’s Board of Directors.

 

21
 

 

Scentech Transaction

 

During the second quarter of 2026, the Company determined not to proceed with its previously disclosed proposed acquisition of an interest in Scentech Medical Ltd. No definitive agreement was executed, and the parties did not reach final terms. The Company has not incurred any termination fees or other material liabilities in connection with the discontinuation of those discussions.

 

Digital Asset Treasury Strategy

 

In September 2025, the Company adopted a digital asset treasury strategy contemplating the allocation of a portion of its treasury assets to cryptocurrencies and related blockchain initiatives. The Company held digital assets as of December 31, 2025, but held no digital assets as of September 30, 2026. The Company has scaled back this initiative, which is currently on hold, while continuing to evaluate other capital deployment opportunities, including operating investments and strategic acquisitions. Any future digital asset holdings would be subject to market price volatility, which could affect results of operations.

 

Capital Markets Activity

 

In January 2026, the Company completed a public offering that generated gross proceeds of approximately $2.0 million, enhancing liquidity and capital resources. The offering consisted of common stock and accompanying warrants, and during the nine months ended September 30, 2026, the Company received approximately $0.8 million from the exercise of outstanding warrants.

 

In February 2026, the Company amended its at-the-market (“ATM”) offering program, increasing the aggregate amount of common stock that may be offered and sold from time to time to approximately $1.8 million. The ATM program provides the Company with additional flexibility to access capital as needed, subject to market conditions. During the nine months ended September 30, 2026, the Company sold shares under its ATM program for combined net proceeds of approximately $1.7 million, with only a de minimis amount remaining available under the program for future issuances.

 

In March 2026, the Company also amended its equity line of credit facility, extending the availability period through December 31, 2028 (subject to earlier utilization) and increasing the total committed capital to $50.0 million. During the nine months ended September 30, 2026, the Company sold shares under the facility for aggregate net proceeds of approximately $720,000, with approximately $48.3 million of remaining capacity as of September 30, 2026, subject to the terms of the facility.

 

These financing activities strengthened the Company’s liquidity and expanded its financing capacity to support ongoing operations, strategic acquisitions and other corporate purposes.

 

Stockholder Rights Plan

 

On September 3, 2026, the Company announced that its Board of Directors adopted a one-year stockholder rights plan intended to protect stockholder interests against certain unsolicited takeover attempts. The rights generally become exercisable if a person or group acquires 15% or more of the Company’s outstanding common stock without Board approval, subject to certain exceptions. The plan is scheduled to expire on September 3, 2027, unless earlier redeemed or terminated by the Board.

 

Settlement Agreements

 

During March 2026, the Company entered into settlement agreements related to certain prior stock purchase transactions and matters involving previously asserted guarantees, including those associated with related parties. In connection with these agreements, the Company paid aggregate settlement amounts of approximately $131,000. The settlements were reviewed and approved by the independent members of the Company’s Board of Directors.

 

Amendment to 2025 Equity Incentive Plan

 

On May 6, 2026, the Company’s stockholders approved an amendment to the Company’s 2025 Equity Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 350,000 shares, from 50,000 shares to 400,000 shares. The amendment was approved at the Company’s 2026 Annual Meeting of Stockholders and is intended to support the Company’s ongoing employee, director, consultant, and strategic incentive compensation programs.

 

Reverse Stock Split

 

On May 7, 2026, our Board of Directors approved a 1-for-40 reverse stock split of our issued and outstanding common stock, as well as a proportional reduction in the number of authorized shares of common stock. The reverse stock split became effective for trading purposes on May 18, 2026.

 

The reverse stock split was undertaken to increase the market price of our common stock and to enable us to regain compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). On June 2, 2026, we received a letter from the Nasdaq Listing Qualifications Department notifying us that we had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), and that the matter is now closed.

 

As a result of the reverse stock split, every 40 shares of our outstanding common stock were automatically combined into one share of common stock, and the number of authorized shares of common stock was reduced proportionately. Unless otherwise indicated, all share and per-share amounts relating to the Company’s common stock in this Quarterly Report on Form 10-Q have been retroactively adjusted to reflect the 1-for-40 reverse stock split for all periods presented. The reverse stock split did not affect stockholders’ relative ownership interests, except with respect to the treatment of fractional shares. As a result of the reverse stock split, the CUSIP number assigned to the Company’s common stock was changed to 75946W504.

 

22
 

 

While the reverse stock split increased the per share trading price of our common stock, there can be no assurance that we will continue to meet Nasdaq’s continued listing standards in the future. We continue to monitor our stock price and may take additional actions, if necessary, to maintain compliance with applicable listing requirements.

 

Corporate Governance

 

On March 11, 2026, the Company adopted Amended and Restated Bylaws, which, among other things, revised the provision relating to the timing of the annual meeting of stockholders so that the date, time and place of the annual meeting may be determined by the Company’s Board of Directors. On March 17, 2026, the Company filed Articles of Restatement with the Florida Department of State, restating the Company’s Articles of Incorporation in their entirety.

 

Business Trends and Uncertainties

 

The insurance intermediary business is highly competitive, and we actively compete with numerous firms for customers and insurance companies, many of which have relationships with insurance companies, or have a significant presence in niche insurance markets that may give them an advantage over us. Other competitive concerns may include the quality of our products and services, our pricing and the ability of some of our customers to self-insure and the entrance of technology companies into the insurance intermediary business. Several insurance companies are engaged in the direct sale of insurance, primarily to individuals, and do not pay commissions to agents and brokers.

 

Insurance Operations

 

Our insurance operations focus on growing RELI Exchange and expanding insurance distribution through our agency partner network and other distribution relationships. RELI Exchange provides independent agency partners with access to insurance carriers, technology and centralized operational support to help them place and service insurance policies. Our agencies generate commission revenue from new and renewal policies placed with third-party insurance carriers, which assume the underwriting risk.

 

Our growth priorities include recruiting additional agency partners, increasing production across our existing network, expanding distribution partnerships and broadening available insurance products. We continue to develop automation and artificial intelligence capabilities to streamline quoting, policy servicing and administrative functions, with the objective of supporting higher policy volumes while improving operating efficiency and customer service.

 

We also evaluate selective acquisitions and other strategic opportunities that complement our insurance platform and are consistent with our capital allocation priorities.

 

Insurance Agency Portfolio

 

Our insurance operations include RELI Exchange and Kush Benefit Solutions. During 2025, the Company sold U.S. Benefits Alliance (“USBA”), Employee Benefits Solutions (“EBS”) and Fortman Insurance Services (“FIS”). During the third quarter of 2026, the Company sold Altruis Benefit Consultants (“ABC”) and Southwestern Montana Insurance Center (“SWM”). UIS Agency (“UIS”), including Commercial Coverage Solutions, was classified as held for sale at September 30, 2026 and subsequently sold on October 13, 2026.

 

For the nine months ended September 30, 2026, ABC, SWM and UIS contributed commission revenue of approximately $4.09 million, $1.06 million and $161,000, respectively, totaling approximately $5.31 million. For the third quarter of 2026, these businesses contributed combined commission revenue of approximately $1.05 million. The results of these businesses are included in consolidated results through their respective disposal dates. Their absence following disposal will affect future revenue and expense comparisons.

 

The Company continues to develop its retained insurance operations through RELI Exchange’s agency partner network, distribution relationships and technology capabilities.

 

23
 

 

Non-GAAP Financial Measure

 

The Company believes certain financial measures which meet the definition of non-GAAP financial measures, as defined in Regulation G of the SEC rules, provide important supplemental information. Adjusted EBITDA (“AEBITDA”), our key financial performance metric, is a non-GAAP financial measure that is not in accordance with, or an alternative to, measures prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”). “AEBITDA” is defined as earnings before interest, taxes, depreciation, and amortization (EBITDA) with additional adjustments as further outlined below. The Company considers AEBITDA an important financial metric because it provides a meaningful financial measure of the quality of the Company’s operational, cash impacted and recurring earnings and operating performance across reporting periods. Other companies may calculate Adjusted EBITDA differently than we do, which might limit its usefulness as a comparative measure to other companies in the industry. AEBITDA is used by management in addition to and in conjunction (and not as a substitute) with the results presented in accordance with GAAP. Management uses AEBITDA to evaluate the Company’s operational performance, including earnings across reporting periods and the merits for implementing cost-cutting measures. We have presented AEBITDA solely as supplemental disclosure because we believe it allows for a more complete analysis of results of operations and assists investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Consistent with Regulation G, a description of such information is provided below herein and tabular reconciliations of this supplemental non-GAAP financial information to our most comparable GAAP information are contained in this Quarterly Report on Form 10-Q under “Results of Operations”.

 

We exclude the following items when calculating AEBITDA, and the following items define our non-GAAP financial measure AEBITDA:

 

  ● Interest and related party interest expense: Unrelated to core Company operations and excluded to provide more meaningful supplemental information regarding the Company’s core operational performance.
  ● Depreciation and amortization: Non-cash charge, excluded to provide more meaningful supplemental information regarding the Company’s core operational performance.
  ● Goodwill and/or asset impairments: Non-cash charge, excluded to provide more meaningful supplemental information regarding the Company’s core operational performance.
  ● Equity-based compensation: Non-cash compensation provided to employees and service providers, (including period amortization cost of service provider prepaid expenses that were prepaid with stock) excluded to provide more meaningful supplemental information regarding the Company’s core cash impacted operational performance.
  ● Other income (expense), net and/or Settlement income: Includes income and expenses unrelated to the Company’s core operations, such as proceeds from the settlement of an arbitration involving a divested business, and other individually de minimis items, excluded to provide more meaningful supplemental information regarding the Company’s core operational performance. Charitable contributions, which are also included in other (income) expense, net, are not excluded.
  ● Gain (Loss) from Equity Method Investment: Includes certain gains and losses on equity method investments that are non-cash, and thus excluded to provide more meaningful supplemental information regarding the Company’s core operational performance.
  ● Unrealized gains (losses) on digital assets, net: This account includes unrealized gains and losses from digital assets and is thus excluded as unrelated to core operations of the company.
  ● Gain on sale: This account includes gains on sale from certain agency divestitures that occurred in the period which are unrelated to primary Company operations and are excluded to provide more meaningful supplemental information regarding the Company’s core operational performance.
  ● Loss on Extinguishment of debt: Non-cash write-off of unamortized debt issuance costs upon the repayment of the Company’s term debt, excluded to provide more meaningful supplemental information regarding the Company’s core operational performance.
  ●

Equity investments impairment loss: Non-cash charge to reduce the carrying value of an equity investment to its estimated fair value, excluded to provide more meaningful supplemental information regarding the Company’s core operational performance.

  ● Transactional costs: This includes expenses related to mergers, acquisitions, financings and refinancings, and amendments or modification to indebtedness. These costs are unrelated to primary Company operations and are excluded to provide more meaningful supplemental information regarding the Company’s core operational performance.
  ● Non-standard costs: This account includes non-recurring non-operational items, related to costs incurred for a legal suit the Company has filed against one of the third parties involved in previously discontinued operations and was excluded to provide more meaningful supplemental information regarding the Company’s core operational performance.

 

Refer to the reconciliation of net (loss) income to AEBITDA, illustrated below in tabular format.

 

24
 

 

Results of Operations

 

RELIANCE GLOBAL GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS ANALYTICS

 

Comparison of the three months ended September 30, 2026 to the three months ended September 30, 2025

 

   Three Months Ended         
   September 30, 2026   September 30, 2025   Value Fluctuation   Percent Fluctuation 
Commission Income  $1,842,997   $2,495,975   $(652,978)   -26%
                     
Commission Expense   783,707    995,945    (212,238)   -21%
Salaries and wages   3,262,869    3,912,326    (649,457)   -17%
General and administrative expenses   948,630    1,120,776    (172,146)   -15%
Marketing and advertising expenses   21,870    66,917    (45,047)   -67%
Depreciation and amortization   216,829    313,694    (96,865)   -31%
Asset Impairments   90,841    -    90,841    - 
Total operating expenses   5,324,747    6,409,658    (1,084,911)   -17%
              -      
Loss from operations   (3,481,749)   (3,913,683)   431,934    -11%
                     
Other income (expense)                    
Interest expense   (127,399)   (246,722)   119,323    -48%
Interest (expense) related parties   -    (4,704)   4,704    -100%
Other income (expense), net   51,630    (16,470)   68,100    -413%
Equity investments impairment loss   (713,771)   -    (713,771)   - 
Gain on sale of business   7,730,012    3,033,554    4,696,458    155%
Gain (loss) on Extinguishment of debt   (117,841)   -    (117,841)   - 
Unrealized gains (losses) on digital assets, net   -    (8,558)   8,558    -
Total other (expense) income   6,822,631    2,757,100    4,065,531    147%
                     
Net income (loss)   3,340,881    (1,156,583)   4,497,464    -
                     
Less: Net loss attributable to non-controlling interests   (6,557)   -    (6,557)   -
Net income (loss) attributable to Reliance Global Group, Inc.  $3,347,438   $(1,156,583)  $4,504,021    -
Non-GAAP Measure                    
AEBITDA  $(1,946,975)  $(707,021)  $(1,239,954)   -

 

Three Months Ended September 30, 2026

 

Commission Income

 

The decrease in consolidated commission income primarily reflected the 2025 divestiture of Employee Benefits Solutions, the third-quarter 2026 divestitures of Altruis Benefit Consultants, Inc. and Southwestern Montana Insurance Center, and lower commission revenue at Kush Benefit Solutions, partially offset by growth at RELI Exchange.

 

Commission Expense

 

The decrease in consolidated commission expense primarily reflected the 2025 and 2026 divestitures and lower commission expense at Kush Benefit Solutions.

 

Salaries and Wages

 

The decrease in consolidated Salaries and Wages was primarily attributable to higher non-cash employee equity awards in the prior-year period, as well as the elimination of compensation costs associated with FIS and EBS following their divestitures, partially offset by increased compensation costs related to additional corporate personnel and compensation adjustments.

 

General and Administrative Expenses

 

The decrease in consolidated General and Administrative Expenses was primarily attributable to higher non-cash director equity awards and consulting costs in the prior-year period, partially offset by growth related costs in 2026.

 

25
 

 

Marketing and Advertising Expenses

 

The decrease in consolidated Marketing and Advertising Expenses reflects changes in the Company’s marketing strategies and related expenditures.

 

Depreciation and Amortization

 

The decrease in consolidated Depreciation and Amortization Expense was primarily attributable to the divestitures of FIS and EBS during 2025 and the elimination of depreciation and amortization associated with the related assets.

 

Asset Impairments

 

During the three months ended September 30, 2026, the Company recognized an impairment loss of approximately $91,000 related to the reclassification of UIS Agency LLC (UIS) to assets as held for sale. No comparable impairment was recognized in the prior-year period.

 

Other Income (Expense)

 

The increase in consolidated total other income was primarily attributable to higher gains on the sales of businesses, including the divestitures of Altruis Benefit Consultants (Altruis) and Southwestern Montana Insurance Center (SWM), which generated aggregate gains of approximately $7.7 million, compared to approximately $3.0 million in the prior-year period. The increase was also attributable to lower interest expense resulting from debt repayments and higher other income primarily related to settlement income, partially offset by an impairment loss of approximately $714,000 on the Company’s investment in Enquantum and a loss on extinguishment of debt of approximately $118,000.

 

AEBITDA

 

The decrease in consolidated AEBITDA was primarily attributable to lower commission revenue resulting from agency divestitures and increased cash compensation costs.

 

RELIANCE GLOBAL GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS ANALYTICS

 

Comparison of the nine months ended September 30, 2026 to the nine months ended September 30, 2025

 

   Nine Months ended         
   September 30, 2026   September 30, 2025   Value Fluctuation   Percent Fluctuation 
Commission Income  $7,780,604   $9,818,872   $(2,038,268)   -21%
                     
Commission Expense   3,192,515    3,454,147    (261,632)   -8%
Salaries and wages   6,443,020    8,705,682    (2,262,662)   -26%
General and administrative expenses   3,462,860    4,129,842    (666,982)   -16%
Marketing and advertising expenses   362,888    201,399    161,489    80%
Depreciation and amortization   774,249    1,020,440    (246,191)   -24%
Asset Impairments   90,841    -    -    - 
Total operating expenses   14,326,373    17,511,511    (3,185,138)   -18%
              -      
Loss from operations   (6,545,769)   (7,692,639)   1,146,870    -15%
              -      
Other income (expense)             -      
Interest expense   (378,444)   (844,846)   466,402    -55%
Interest (expense) related parties   -    (50,811)   50,811    -100%
Other income (expense), net   12,363    (41,068)   53,431    -130%
Gain (Loss) from Equity Method Investment   (120,384)   -    (120,384)   - 
Equity investments impairment loss   (713,771)   -    (713,771)   - 
Gain on sale of business   7,730,012    3,033,554    4,696,458    155%
Gain (loss) on Extinguishment of debt   (117,841)   -    (117,841)   - 
Unrealized gains (losses) on digital assets, net   9,263    (8,558)   17,821    -208%
Total other (expense) income   6,421,198    2,088,271    4,332,927    207%
                     
Net loss   (124,571)   (5,604,367)   5,479,796    -98%
                     
Less: Net loss attributable to non-controlling interests   (9,470)   -    (9,470)   - 
Net loss attributable to Reliance Global Group, Inc.  $(115,101)  $(5,604,367)  $5,489,266    -98%
Non-GAAP Measure                    
AEBITDA  $(3,519,218)  $(918,706)  $(2,600,512)   - 

 

26
 

 

Nine Months Ended September 30, 2026

 

Commission Income

 

The decrease in consolidated Commission Income was primarily attributable to the divestitures of Fortman Insurance Services (FIS) and Employee Benefit Solutions (EBS) during 2025, which eliminated commission revenue previously generated by these operations, as well as some declines in organic revenue offset by organic revenue growth in certain of our retained businesses.

 

Commission Expense

 

The decrease in consolidated Commission Expense was primarily attributable to lower commission revenue, including the impact of the divestitures of FIS and EBS during 2025.

 

Salaries and Wages

 

The decrease in consolidated Salaries and Wages was primarily attributable to higher non-cash employee equity awards in the prior-year period, as well as the elimination of compensation costs associated with FIS and EBS following their divestitures, partially offset by increased compensation costs related to additional corporate personnel and compensation adjustments.

 

General and Administrative Expenses

 

The decrease in consolidated General and Administrative Expenses was primarily attributable to higher acquisition-related share expenses and non-cash director equity awards in the prior-year period, partially offset by increased growth related legal, consulting, and investor relations costs in 2026.

 

Marketing and Advertising Expenses

 

The increase in consolidated Marketing and Advertising Expenses reflects changes in the Company’s marketing strategies and related expenditures.

 

Depreciation and Amortization

 

The decrease in consolidated Depreciation and Amortization Expense was primarily attributable to the divestitures of FIS and EBS during 2025 and the elimination of depreciation and amortization associated with the related assets.

 

Asset Impairments

 

During the nine months ended September 30, 2026, the Company recognized an impairment loss of approximately $91,000 related to the reclassification of UIS Agency LLC (UIS) to assets held for sale. No comparable impairment was recognized in the prior-year period.

 

Other Income (Expense)

 

The increase in consolidated total other income was primarily attributable to higher gains on the sales of businesses, including the divestitures of Altruis Benefit Consultants (Altruis) and Southwestern Montana Insurance Center (SWM), which generated aggregate gains of approximately $7.7 million, compared to approximately $3.0 million in the prior-year period. The increase was also attributable to lower interest expense resulting from debt repayments, the repayment of related-party debt, higher settlement income, and gains on digital assets, partially offset by an impairment loss of approximately $714,000 on the Company’s investment in Enquantum, a loss of approximately $120,000 from an equity method investment, and a loss on extinguishment of debt of approximately $118,000.

 

AEBITDA

 

The decrease in consolidated AEBITDA was primarily attributable to lower commission revenue reflecting the agency divestitures and declines in certain organic revenue offset by certain organic growth, as well as increased cash compensation costs.

 

27
 

 

Insurance Segment – Results of Operations

 

Insurance segment comparison of the three months ended September 30, 2026 to the three months ended September 30, 2025

 

   September 30, 2026  September 30, 2025  Change  % Change
   Insurance  Insurance      
             
Commission income  $1,842,997   $2,495,975   $(652,978)   -26%
Total Revenue   1,842,997    2,495,975    (652,978)   -26%
Total operating expenses                    
Commission expense   783,707    995,945    (212,238)   -21%
Salaries and wages   792,917    869,538    (76,621)   -9%
General and administrative expenses   271,117    258,364    12,753    5%
Marketing and advertising   3,728    8,583    (4,855)   -57%
Interest expense   119,693    240,491    (120,798)   -50%
Interest expense related parties   -    4,490    (4,490)   -100%
Insurance Segment net income (loss)  $(128,164)  $118,563   $(246,727)   -208%

 

Insurance segment revenue decreased compared to the prior-year period. Commission Income decreased, primarily attributable to portfolio realignments completed during 2025, including the divestiture of Employee Benefits Solutions (EBS), which eliminated commission revenue previously generated by these operations as well as a decline in organic revenue from retained businesses.

 

Total operating expenses decreased overall compared to the prior-year period, primarily reflecting cost reductions associated with the divestiture of certain business operations and ongoing efficiency initiatives.

 

  ● Commission expense decreased, primarily attributable to the Company’s portfolio realignment initiatives completed during 2025, including the divestitures of Employee Benefits Solutions (EBS), which eliminated commission expense previously incurred by these operations.

 

  ● Salaries and wages decreased significantly due to the elimination of personnel costs associated with the divested FIS and EBS businesses.

 

  ● General and administrative expenses increased due to expenses associated with the sale of Altruis, partially offset by general operational efficiencies.

 

  ● Marketing and advertising expenses decreased substantially, consistent with the Company’s current marketing strategy.

 

Total interest expense (including related party interest) decreased due to the repayment of outstanding loan balances and periodic paydowns of related party obligations.

 

As a result of the above factors, the Insurance segment reported a net loss compared to net income in the prior-year period. The decline in profitability was primarily attributable to lower commission revenue following the divestitures, partially offset by reductions in operating expenses and lower interest expense.

 

28
 

 

Insurance segment comparison of the nine months ended September 30, 2026 to the nine months ended September 30, 2025

 

   September 30, 2026  September 30, 2025  Change  % Change
   Insurance  Insurance      
             
Commission income  $7,780,604   $9,818,872   $(2,038,268)   -21%
Total Revenue   7,780,604    9,818,872    (2,038,268)   -21%
Total operating expenses                    
Commission expense   3,192,515    3,454,147    (261,632)   -8%
Salaries and wages   2,327,956    3,228,657    (900,701)   -28%
General and administrative expenses   796,665    970,902    (174,237)   -18%
Marketing and advertising   10,583    42,574    (31,991)   -75%
Interest expense   360,743    829,090    (468,347)   -56%
Interest expense related parties   -     50,377    (50,377)   -100%
Insurance Segment Net income  $1,092,143   $1,243,124   $(150,981)   -12%

 

Insurance segment revenue decreased compared to the prior-year period. Commission Income decreased, primarily attributable to portfolio realignments completed during 2025 and 2026, including the divestitures of Fortman Insurance Services (FIS), Employee Benefits Solutions (EBS), which eliminated commission revenue previously generated by these operations as well as a general decline in certain commissions, offset by certain commission revenue growth.

 

Total operating expenses decreased overall compared to the prior-year period, primarily reflecting cost reductions associated with the divestiture of certain business operations and ongoing efficiency initiatives.

 

  ● Commission expense decreased, primarily attributable to the Company’s portfolio realignment initiatives completed during 2025, including the divestiture of Employee Benefits Solutions (EBS) which eliminated commission expense previously incurred by these operations, offset by higher commission rates of our retained businesses due to general market conditions.

 

  ● Salaries and wages decreased significantly due to the elimination of personnel costs associated with the divested FIS and EBS businesses.

 

  ● General and administrative expenses declined as a result of the agency divestitures and general operational efficiencies.

 

  ● Marketing and advertising expenses decreased substantially, consistent with the Company’s current marketing strategy.

 

  ● Total interest expense (including related party interest) decreased significantly due to the repayment of outstanding loan balances and periodic paydowns of related party obligations.

 

As a result of the above factors, Insurance segment profitability declined compared to the prior-year period. The decrease was primarily driven by the decline in revenue following the divestitures partially offset by reductions in operating expenses and lower interest expense.

 

29
 

 

Non-GAAP Reconciliation from Net Income (Loss) to AEBITDA

 

The following table provides a reconciliation from net income (loss) to consolidated AEBITDA for periods ended September 30, 2026, and September 30, 2025

 

   Three Months Ended September 30,   Nine Months Ended September 30, 
   2026   2025   2026   2025 
                 
Net income (loss)  $3,340,881   $(1,156,583)  $(124,571)  $(5,604,367)
Adjustments:                    
Interest and related party interest expense   127,399    251,426    378,444    895,657 
Depreciation and amortization   216,829    313,694    774,249    1,020,440 
Asset Impairments   90,841    -    90,841    - 
Share based compensation employees directors and third parties   1,160,813    2,808,446    1,562,707    5,312,988 
Other (income) expense, net   

-

   16,470    -   41,068 
Settlement income   (70,000)   -    (70,000)   - 
Transactional costs   84,662    61,450    656,391    452,686 
Non-standard costs   -    23,072    -    (12,182)
Loss from equity method investment   -    -    120,384    - 
Gain on sale of business   (7,730,012)   (3,033,554)   (7,730,012)   (3,033,554)
Loss on extinguishment of debt
   117,841    -    117,841     
Equity investments impairment loss
   713,771    -    713,771    - 
Unrealized (gains) losses on digital assets, net   -    8,558    (9,263)   8,558 
Total adjustments  $(5,287,856)  $449,562   $(3,394,646)  $4,685,661 
                     
AEBITDA  $(1,946,975)  $(707,021)  $(3,519,218)  $(918,706)

 

Liquidity and capital resources

 

On July 22, 2026, the SEC approved Nasdaq’s adoption of a new continued listing standard requiring listed companies to maintain a minimum Market Value of Listed Securities of $5 million. On July 29, 2026, the approval was stayed following petitions for review, and on September 11, 2026, the SEC granted the petitions and continued the stay pending further review. Accordingly, the new requirement is not currently in effect. Management continues to monitor developments and evaluate alternatives available to maintain compliance with Nasdaq’s continued listing requirements.

 

Overall, the Company continues to maintain flexible access to capital to support its operations and growth initiatives. Management believes that existing cash balances, anticipated operating cash flows, available financing facilities, and access to capital markets, provide sufficient resources to fund current obligations and planned expenditures for at least the next twelve months.

 

During 2025, the Company further diversified its capital structure through a combination of equity-based financing arrangements, including the Equity Line of Credit (“ELOC”) with White Lion Capital, LLC, the At-the-Market (“ATM”) Program with H.C. Wainwright & Co., LLC, and the Private Placement-2025 completed in June 2025. During the first quarter of 2026, the Company completed a public offering generating gross proceeds of approximately $2.0 million before offering expenses. These financing vehicles provide the Company with multiple sources of capital that may be accessed opportunistically and at prevailing market prices while maintaining control over timing and issuance levels.

 

During the nine months ended September 30, 2026, the Company sold 514,496 shares of Common Stock under the ATM Program for net proceeds of approximately $1.7 million. As of September 30, 2026, approximately $184 of Common Stock remained available for issuance under the ATM Program. During the nine months ended September 30, 2026, the Company sold 254,666 shares under the ELOC Agreement for net proceeds of approximately $720,000. As of September 30, 2026, remaining capacity under the facility was approximately $48.3 million. Subsequent to September 30, 2026, we paid $3.0 million in cash at the closing of the Oblivus acquisition and deposited an additional $375,000 in escrow, paid approximately $0.8 million in cash in settlement of certain equity awards and, through LGG, funded an additional $225,000 to Innervate. The ATM Program has been substantially fully utilized. As discussed elsewhere in this Report, including under Part II, Item 1A (Risk Factors), our access to the capital markets and additional financing, including these financing vehicles, is subject to certain risks that may be outside of our control.

 

Management intends to use the net proceeds from these financings for general corporate purposes, including working capital, technology development, and to advance its growth initiatives. Management continues to evaluate additional financing alternatives and believes that the combination of strengthened balance-sheet metrics, flexible equity facilities, and expected operational cash flows provides adequate liquidity to support both near-term needs and long-term strategic growth objectives.

 

As of September 30, 2026, we had an unrestricted cash balance of approximately $6.7 million and working capital of approximately $7 million, compared with a combined unrestricted and restricted total cash balance of approximately $2,731,000 and working capital of approximately $1,875,000 as of December 31, 2025.

 

30
 

 

Inflation

 

The Company generally may be impacted by rising costs for certain inflation-sensitive operating expenses such as labor, employee benefits, and facility leases. The Company believes inflation could have a material impact on pricing and operating expenses in future periods due to the state of the economy and current inflation rates.

 

Off-balance sheet arrangements

 

We did not have any off-balance sheet arrangements, as such term is defined in Regulation S-K, during the nine months ended September 30, 2026.

 

Cash Flows

 

   

Nine Months Ended

September 30,

 
    2026     2025  
Net cash used in operating activities   $ (3,852,000 )      (1,469,000 )
Net cash provided by investing activities     8,474,000       4,289,000  
Net cash used in financing activities     (653,000 )      (1,115,000 )
Net increase in cash, cash equivalents, and restricted cash   $ 3,968,000     $ 1,706,000  

 

Operating Activities

 

Net cash used in operating activities for the nine months ended September 30, 2026 was approximately $3,852,000 compared to approximately $1,469,000 for the nine months ended September 30, 2025. Cash used in operating activities for the 2026 period reflects a net loss of approximately $125,000, adjusted for net non-cash items of approximately $4,314,000 that reduced operating cash flows, partially offset by approximately $586,000 of cash provided by changes in operating assets and liabilities. The non-cash adjustments consisted primarily of a gain on sale of businesses of approximately $7,730,000, partially offset by depreciation and amortization of approximately $774,000, equity-based compensation and equity-based payments to third parties of approximately $1,591,000, impairment losses of approximately $805,000, loss on equity method investment of approximately $120,000, and loss on extinguishment of debt of approximately $118,000.

 

Investing Activities

 

Net cash provided by investing activities for the nine months ended September 30, 2026 was approximately $8,474,000 compared to approximately $4,289,000 for the nine months ended September 30, 2025. Cash provided by investing activities for the 2026 period consisted primarily of proceeds from sales of businesses of approximately $10,163,000 and proceeds from sales of crypto assets of approximately $118,000, partially offset by equity investments of approximately $1,784,000 and purchases of intangible assets and property and equipment of approximately $24,000.

 

Financing Activities

 

Net cash used in financing activities for the nine months ended September 30, 2026 was approximately $653,000 compared to approximately $1,115,000 for the nine months ended September 30, 2025. Cash used in financing activities for the 2026 period consisted primarily of principal repayments of debt of approximately $5,235,000, payments of loans payable to related parties of approximately $287,000, principal repayments of short-term financings of approximately $110,000, and cash paid for deemed dividends of approximately $131,000, partially offset by proceeds of approximately $2,526,000 from common shares issued through a public offering, approximately $1,712,000 from common shares issued through an at-the-market offering, approximately $151,000 from short-term financings, and approximately $720,000 from common shares issued through an equity line of credit.

 

Significant Accounting Policies and Estimates

 

We describe our significant accounting policies in Note 1, Summary of Significant Accounting Policies, of the Notes to Consolidated Financial Statements, and our critical accounting estimates in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. There have been no significant changes in our significant accounting policies or critical accounting estimates since the end of fiscal year 2025.

 

31
 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not applicable.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to a company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

 

Our Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2026, and determined them to be effective as of September 30, 2026.

 

Changes in Internal Control over Financial Reporting

 

There have been no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

32
 

 

PART II

 

Item 1. Legal Proceedings.

 

We are subject to various legal proceedings and claims, either asserted or unasserted, arising in the ordinary course of business. While the outcome of these claims cannot be predicted with certainty, management does not believe the outcome of any of these matters will have a material adverse effect on our business, financial position, results of operations, or cash flows, and accordingly, no legal contingencies are accrued as of September 30, 2026. Litigation relating to the insurance brokerage industry is not uncommon. As such we, from time to time have been subject to such litigation. No assurances can be given with respect to the extent or outcome of any such litigation in the future.

 

Item 1A. Risk Factors.

 

Investing in our common stock involves a high degree of risk. You should consider carefully the information disclosed in Part I, Item 1A, “Risk Factors,” contained in our Annual Report on Form 10-K for the year ended December 31, 2025, as the same may be updated from time to time. As a smaller reporting company, the Company is not required to disclose material changes to the risk factors that were contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as updated from time to time. The following risk factors are applicable to our recent acquisition of the Oblivus GPU cloud business, our recently announced expansion into the technology sector through EZRA International Group LLC and life sciences sector through LifeSci Global Group LLC, as well as our qualification for continued listing on the Nasdaq Capital Market, and are being provided to supplement those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025.

 

Failure to satisfy Nasdaq’s new minimum Market Value of Listed Securities requirement, its minimum bid price requirement or other continued listing requirements could result in the delisting of our common stock.

 

In July 2026, the SEC approved Nasdaq’s adoption of a new continued listing standard requiring companies listed on The Nasdaq Capital Market to maintain a minimum Market Value of Listed Securities (“MVLS”) of $5.0 million. Under the new rule, if a company’s MVLS remains below $5.0 million for 30 consecutive business days, Nasdaq may issue a Staff Delisting Determination without first providing a customary compliance period. Although a company may appeal such determination, its common stock would generally be suspended from trading on Nasdaq during the appeal process. On July 29, 2026, the approval order was stayed after notices of intention to petition for Commission review were filed, and on September 11, 2026 the SEC granted the petitions for review and continued the stay pending further order. While the stay remains in effect the new requirement is not being applied, and Nasdaq has proposed that, if the stay ends, the first business day counted toward the 30-business-day period will be the business day after the stay ends.

 

Based on the current market price of our common stock, our Market Value of Listed Securities has recently been below the $5.0 million threshold. Accordingly, there can be no assurance that we will satisfy the MVLS continued listing requirement within the applicable period prescribed by Nasdaq’s rules or otherwise maintain compliance with Nasdaq’s continued listing standards.

 

On December 12, 2025, the Company received a notice from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) that it was not in compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2). On June 2, 2026, Nasdaq notified the Company that it had regained compliance with the minimum bid price requirement and that the matter was closed. Nasdaq further noted that, pursuant to Listing Rule 5810(c)(3)(A)(iv), because of the Company’s prior reverse stock splits, the Company may not be eligible for a future compliance period under the minimum bid price rule if it were to become non-compliant with that requirement again.

 

Any delisting of our common stock from Nasdaq could materially and adversely affect the liquidity and market price of our common stock, reduce analyst coverage and institutional investor interest, impair our ability to access the capital markets, including under financing arrangements that require a Nasdaq listing (including under our existing at-the-market offering program which requires Nasdaq listing), and adversely affect our business, financial condition, and results of operations. If our common stock were delisted from Nasdaq, it would likely trade on an over-the-counter market, where trading is generally characterized by lower trading volumes, reduced liquidity, wider bid-ask spreads, and greater price volatility than trading on a national securities exchange.

 

33
 

 

Risks Related to Our Technology Investment Strategy and Enquantum

 

Our expansion into the technology sector through EZRA International Group and Scale51 represents a new line of business in which we have limited operating experience.

 

In January 2026, we launched EZRA International Group and introduced our Scale51 operating model, under which we intend to pursue majority ownership positions in technology-driven businesses. Operating, evaluating, and managing technology-focused businesses requires expertise that differs materially from the expertise required to operate our insurance brokerage and InsurTech businesses, and our management team has limited direct experience operating businesses in many of the technology subsectors we may target, including post-quantum cryptography, cybersecurity, artificial intelligence, and other emerging technology fields. Successful execution of our Scale51 strategy depends on our ability to identify suitable investment opportunities, conduct adequate technical and commercial diligence, negotiate transactions on favorable terms, secure required regulatory and third-party approvals, integrate or oversee acquired or portfolio companies, and recruit and retain personnel with relevant technical expertise. We may be unable to do any of these things effectively. If our Scale51 strategy proves unsuccessful, our financial condition, results of operations, and the market price of our common stock could be materially adversely affected.

 

Investments in early-stage technology companies, including Enquantum, are highly speculative and subject to a substantial risk of loss.

 

Enquantum is an early-stage company that has generated no revenue, has a shareholders’ deficit, has current liabilities in excess of current assets, and ceased operations during the third quarter of 2026. Early-stage technology companies are subject to numerous risks, including the lengthy, expensive, and uncertain nature of technology development; the possibility that products or technologies will fail to perform as intended or fail to achieve commercial acceptance; reliance on a small number of key personnel; the need to secure and maintain intellectual property protection; competition from larger and better-capitalized companies and from alternative or substitute technologies; and dependence on additional capital, which may be unavailable on acceptable terms or at all. Many early-stage technology companies fail to achieve commercialization and ultimately cease operations, as Enquantum has. We have written down our investment in Enquantum to zero, and we may not realize any return on our investment.

 

We have lost substantially all of our investment in Enquantum, and we may not recover any of it.

 

Through September 30, 2026, we funded an aggregate of $834,155 to Enquantum Ltd., an Israeli early-stage company focused on post-quantum encryption and data protection technologies, under a Share Purchase Agreement contemplating our acquisition of up to 51% of its shares. During the third quarter of 2026, Enquantum ceased operations. As a result, we discontinued equity method accounting and recognized an impairment loss of $713,771 that reduced the carrying value of our investment to zero, in addition to equity method losses of $120,384 recognized in the nine months ended September 30, 2026. We retain approximately 34% of Enquantum’s issued and outstanding shares and are evaluating our rights and remedies under the Share Purchase Agreement, but Enquantum has no committed funding and we may not recover any part of our investment. Because Enquantum is an Israeli company, pursuing any claim could require proceedings in Israel, which could be costly and time-consuming and may not succeed.

 

34
 

 

Risks Related to Our Life Sciences Investment Strategy and LGG

 

Our expansion into the life sciences sector represents a new line of business in which we have limited operating experience.

 

Through LGG, we have entered the healthcare and life sciences sector, a field in which we have not previously operated and in which our management team has limited direct operating experience. The life sciences sector is highly specialized and differs materially from the insurance and digital asset businesses that have historically constituted our principal lines of business. Successfully evaluating, executing, and managing investments in healthcare-related companies requires scientific, clinical, regulatory, and commercial expertise that we may not possess internally and that we may be required to obtain through hires, advisors, or third-party consultants, any of which may be costly or unavailable on acceptable terms. Our lack of historical experience in the sector may impair our ability to identify suitable investment opportunities, conduct adequate diligence, anticipate sector-specific risks, or realize the anticipated benefits of our life sciences strategy. If our life sciences strategy proves unsuccessful, our financial condition, results of operations, and the market price of our common stock could be materially adversely affected.

 

Investments in early-stage life sciences companies, including Innervate, are highly speculative and subject to a substantial risk of loss.

 

LGG’s initial investment is in Innervate, an early-stage life sciences company developing radiopharmaceutical product candidates. Early-stage life sciences companies are subject to numerous risks that are unique to the sector, including the lengthy, expensive, and uncertain nature of preclinical and clinical development; the need to obtain regulatory approval from the U.S. Food and Drug Administration and comparable foreign authorities before any product candidate may be commercialized; the possibility that product candidates will fail to demonstrate safety or efficacy at any stage of development; reliance on third-party manufacturers, contract research organizations, and clinical investigators; the need to secure and maintain patent and other intellectual property protection; potential product liability exposure; competition from larger and better-capitalized companies; and dependence on additional capital, which may be unavailable on acceptable terms or at all. Radiopharmaceutical products in particular are subject to specialized regulatory requirements relating to the handling, transportation, manufacture, and administration of radioactive materials. Many early-stage life sciences companies fail to bring any product to market and ultimately cease operations. We may be required to write down or write off all or a substantial portion of our investment in Innervate, and we may not realize any return on our investment.

 

LGG is a newly formed entity with no operating history, and we may not realize the anticipated benefits of our life sciences platform strategy.

 

LGG was formed in April 2026 and has no operating history. We expect LGG to serve as the platform through which we pursue additional investments in the healthcare and life sciences sector, but there can be no assurance that LGG will identify, complete, or successfully manage future investments, or that any such investments will generate returns. Our ability to deploy capital through LGG is dependent on, among other things, the availability of suitable investment opportunities, our continued willingness and ability to fund LGG, the performance of LGG’s portfolio companies, and the cooperation of our minority partner in LGG. The formation of LGG and the establishment of related governance, accounting, and compliance infrastructure may also divert management attention and resources from our other lines of business. If LGG fails to achieve its strategic objectives, we may not recover the capital we have committed to LGG and our financial condition and results of operations could be materially and adversely affected.

 

We have committed capital to LGG and may be required to commit additional capital, which may not be available on favorable terms.

 

In connection with the formation of LGG, we entered into a promissory note providing for borrowings by LGG of up to $2.0 million, $950,000 of which had been advanced as of September 30, 2026. We may, in the future, be required or elect to provide additional debt or equity financing to LGG to fund follow-on investments in Innervate, to support new investments by LGG, or to fund LGG’s operating expenses. Any such additional funding requirements could be substantial and may exceed amounts we currently anticipate. We may not have sufficient capital available to satisfy these funding needs from cash on hand, and any required external financing may not be available on acceptable terms, or at all. To the extent we are unable or unwilling to provide additional funding to LGG, the value of our existing investments in LGG and its portfolio companies could be impaired. Conversely, our funding of LGG may reduce the capital available for our other business lines and strategic priorities.

 

35
 

 

Our investment in LGG and Innervate involves significant related party transactions and conflicts of interest.

 

LGG is owned approximately 51% by us and approximately 49% by LifeSci Management Group LLC, an entity owned by certain members of our management and Board of Directors. As a result, members of our management and Board of Directors have direct and indirect economic interests in LGG that differ from those of our public stockholders. In addition, one of our directors serves as the chief executive officer of Innervate, the company in which LGG made its initial investment. These overlapping relationships create actual and potential conflicts of interest with respect to, among other matters, the negotiation of the terms of our funding arrangements with LGG, decisions regarding additional capital commitments to LGG, the selection, valuation, and timing of LGG investments, decisions concerning Innervate (including any future financings, strategic transactions, or exits), the allocation of business opportunities between us and LGG, and the management of LGG’s portfolio. Although the formation of LGG, the related financing arrangements, and the Innervate investment were reviewed and approved by the independent and disinterested members of our Board of Directors, the existence of these conflicts may result in decisions that are less favorable to us than those that would be made in arm’s-length transactions with unrelated third parties, and could expose us to litigation, regulatory scrutiny, or reputational harm. Future related party transactions involving LGG, its minority owner, or its portfolio companies may arise, and we cannot assure you that the procedures we have implemented will be adequate to mitigate the risks associated with such transactions.

 

Our minority ownership position in Innervate limits our ability to control or influence its strategic direction.

 

LGG holds a minority equity interest in Innervate. Although LGG has obtained certain additional rights in connection with its investment, LGG does not control Innervate, and key strategic, operational, financing, and personnel decisions affecting Innervate may be made without LGG’s consent. Innervate may pursue a strategy with which we disagree, may issue additional equity that dilutes LGG’s ownership interest, may enter into transactions on terms that we view as unfavorable, or may experience disputes among its equity holders or management. Our director’s role as chief executive officer of Innervate does not assure that Innervate’s actions will align with our interests, and any decisions made by that director in his capacity as an officer of Innervate are subject to fiduciary duties owed to Innervate and its other equity holders, which may diverge from his duties to us. The illiquid and privately held nature of LGG’s investment in Innervate may also make it difficult or impossible for us to exit the investment on a timely basis or at a favorable price.

 

Consolidation of LGG, and any future consolidation of Innervate, may introduce volatility and complexity into our financial statements.

 

We consolidate LGG in our financial statements as a majority-owned subsidiary, with the noncontrolling interest of LifeSci Management Group LLC reflected accordingly. As LGG’s portfolio grows, our consolidated financial statements will reflect LGG’s investment activity, including changes in the fair value of its portfolio investments and operating expenses, which may introduce volatility and complexity into our reported results. Application of the relevant accounting standards to LGG, its investments, and its capital structure requires significant judgment, and changes in our or LGG’s circumstances—including changes in ownership percentages, governance rights, or the financial condition of portfolio companies—may require us to revise our accounting conclusions, recognize impairment charges, or restate prior period financial statements. In addition, the integration of life sciences-related accounting, valuation, and disclosure processes into our financial reporting function may strain our internal controls over financial reporting, particularly given our status as a smaller reporting company.

 

Innervate’s radiopharmaceutical product candidates are subject to specialized and overlapping regulatory regimes that increase the cost, complexity, and risk of development.

 

Radiopharmaceutical products are subject not only to the regulatory requirements applicable to pharmaceutical products generally, including the U.S. Food and Drug Administration’s investigational new drug, new drug application, and biologics license application processes, but also to the requirements of the U.S. Nuclear Regulatory Commission, Agreement State radiation control programs, the U.S. Department of Transportation, and analogous foreign authorities governing the production, handling, storage, transportation, and administration of radioactive materials. These overlapping regimes can lengthen development timelines, increase costs, and create the risk of inconsistent or conflicting requirements. Failure to obtain or maintain any required license, registration, or authorization, or any violation of applicable radiation safety or transportation requirements, could delay or prevent the development or commercialization of Innervate’s product candidates and adversely affect the value of LGG’s investment.

 

36
 

 

Innervate depends on the availability of medical radioisotopes and specialized manufacturing infrastructure, the supply of which is limited and subject to disruption.

 

Radiopharmaceutical product candidates require medical radioisotopes, many of which are produced by a small number of nuclear reactors and cyclotrons worldwide and are subject to supply constraints, geopolitical risk, aging production infrastructure, and short half-lives that make stockpiling impractical. In addition, the manufacture, compounding, and distribution of radiopharmaceutical products require specialized facilities, equipment, and personnel that are not widely available. Disruptions in isotope supply or manufacturing capacity, the loss of a key supplier or contract manufacturer, or the inability to secure manufacturing capacity on commercially reasonable terms could delay clinical development, impair commercialization, or result in increased costs for Innervate, any of which could materially adversely affect the value of LGG’s investment.

 

Even if Innervate’s product candidates obtain regulatory approval, commercial success will depend on coverage, pricing, and reimbursement determinations that are outside Innervate’s control.

 

The commercial viability of any approved radiopharmaceutical product depends on the willingness of government payors, including Medicare and Medicaid, and private third-party payors to provide adequate coverage and reimbursement. Coverage and reimbursement determinations for radiopharmaceutical products, particularly those administered in hospital outpatient or imaging settings, are subject to evolving payment methodologies, separate payment policies, bundling rules, and ongoing legislative and regulatory reform efforts in the United States and abroad. There can be no assurance that Innervate’s product candidates, if approved, will receive favorable coverage or reimbursement, and inadequate reimbursement could limit market acceptance, pricing, and ultimately the value of LGG’s investment.

 

Innervate’s success depends on its ability to obtain, maintain, and enforce intellectual property rights, which is uncertain and expensive.

 

The value of LGG’s investment in Innervate is substantially dependent on Innervate’s ability to obtain, maintain, defend, and enforce patent and other intellectual property protection for its product candidates, technologies, and know-how. The patent positions of life sciences companies are highly uncertain and involve complex legal, scientific, and factual questions. Innervate may be unable to obtain meaningful patent protection in relevant jurisdictions, issued patents may be narrowed, invalidated, or held unenforceable, and competitors may develop products that design around Innervate’s patents. Innervate may also be subject to claims that its product candidates infringe third-party intellectual property rights, which could result in injunctive relief, damages, or the need to obtain licenses on commercially unreasonable terms. Any failure to protect or defend Innervate’s intellectual property could materially adversely affect Innervate’s prospects and the value of LGG’s investment.

 

Innervate is exposed to product liability and clinical trial liability risks that may not be adequately covered by insurance.

 

The development, testing, and any commercialization of radiopharmaceutical product candidates involves inherent risk of product liability claims, including claims arising from radiation exposure, adverse events in clinical trials, contamination, off-target effects, manufacturing defects, and the prescribing or administration of approved products. Such claims may result in substantial damages, regulatory action, the suspension or termination of clinical trials, recalls, reputational harm, and significant defense costs. Insurance coverage for clinical trial liability and product liability in the radiopharmaceutical sector may be limited, expensive, or unavailable, and Innervate may not maintain coverage that is adequate to address all potential claims. Any uninsured or underinsured liability could materially impair Innervate’s operations and the value of LGG’s investment.

 

Innervate is subject to a broad range of healthcare laws and regulations, violations of which could result in significant penalties.

 

Innervate’s current and future operations may be subject to extensive U.S. federal and state, and analogous foreign, healthcare laws and regulations, including, among others, the federal Anti-Kickback Statute, the federal False Claims Act, the federal Physician Payments Sunshine Act, the Health Insurance Portability and Accountability Act, the Foreign Corrupt Practices Act, and laws governing the marketing and promotion of pharmaceutical products. These laws are subject to evolving interpretation and aggressive enforcement, and even unintentional violations may give rise to substantial civil and criminal penalties, exclusion from federal healthcare programs, corporate integrity obligations, and reputational harm. Any government investigation or enforcement action involving Innervate, even if ultimately resolved without findings of wrongdoing, could materially adversely affect Innervate and the value of LGG’s investment.

 

37
 

 

The fair value of LGG’s investment in Innervate is inherently uncertain and may be subject to material adjustment.

 

Innervate is a privately held company with no public trading market for its securities, and the fair value of LGG’s investment will be determined based on management’s estimates and judgments, including assumptions regarding Innervate’s product development progress, capital needs, comparable company valuations, the rights and preferences of Innervate’s various classes of equity, and broader market conditions. These valuation determinations are inherently subjective and may be required to be revised materially as a result of subsequent events, including the results of clinical or preclinical studies, regulatory developments, financing rounds at lower valuations (so-called “down rounds”), changes in market conditions, or new information regarding Innervate. Any downward adjustment in the fair value of LGG’s investment could result in material non-cash charges to our consolidated results of operations.

 

Future investments by LGG may expose us to additional, and potentially different, life sciences-related risks.

 

We have stated our expectation that LGG will serve as a platform for additional investments in the healthcare and life sciences sector. Future investments may involve different therapeutic modalities, disease areas, regulatory pathways, geographies, or stages of development than the Innervate investment, and may expose us to risks that we have not previously encountered. Future investments may also involve additional related party considerations, larger capital commitments, the use of leverage, the issuance of equity or debt securities by us or our subsidiaries, or the assumption of contingent liabilities. We may be unable to identify suitable investments, complete acquisitions on acceptable terms, integrate or oversee acquired or portfolio companies, or realize the strategic and financial benefits we anticipate. Any failure to execute on LGG’s investment strategy could materially adversely affect our financial condition, results of operations, and the market price of our common stock.

 

Our expansion into the life sciences sector, alongside our existing insurance and digital asset businesses, may adversely affect investor perceptions of our strategic focus and capital discipline.

 

Within a relatively short period, we have announced significant new strategic initiatives, including our digital asset treasury strategy and, through LGG, our expansion into the healthcare and life sciences sector. Investors, analysts, rating agencies, lenders, customers, and regulators may view these initiatives as evidence of strategic drift, lack of focus, or insufficient capital discipline, particularly when undertaken alongside related party arrangements and during a period in which we are addressing Nasdaq listing compliance matters. Negative perceptions could adversely affect our access to capital, the cost of capital, our relationships with counterparties, our ability to attract and retain personnel, and the market price of our common stock, regardless of the underlying performance of any individual business line.

 

Risks Related to Our GPU Cloud Business and Related Changes in Our Business

 

We recently acquired the Oblivus GPU cloud business, which has a limited operating history, and we have limited experience operating a GPU cloud computing business.

 

On November 3, 2026, through our wholly owned subsidiary GPU Exchange Corp., we acquired the Oblivus GPU cloud computing platform and related assets from Skyportal Inc. for $3,000,000 in cash at closing, with up to $750,000 of additional cash payments contingent on revenue milestones. We did not acquire any contracts of the seller or assume any pre-closing liabilities, so the platform’s customer and supplier relationships are not governed by assumed contracts and may not continue. The platform has a limited operating history, depends on third-party GPU capacity and pricing, and competes with larger and better-capitalized providers of cloud and GPU computing capacity. Our management has limited experience operating this type of business, and the transaction may divert management attention from our insurance brokerage and InsurTech businesses. We have not determined whether we will exercise our right to invest up to $500,000 in the seller, and any such investment would expose us to additional risk. In addition, our ability to recover losses if the acquired business is not as represented is limited, as the seller’s liability for most breaches of its representations is capped at $375,000 and generally survives for only twelve months after closing.

 

We will depend on third parties for GPU capacity and data centers, and pricing pressure, fast-changing technology and larger competitors could reduce our margins and growth.

 

The Oblivus platform sources, aggregates and resells GPU capacity from data centers, cloud providers and GPU owners, and its marketplace depends on third-party hardware owners making their capacity available. We did not acquire the seller’s supplier or customer contracts, and these suppliers may withdraw capacity, raise prices or favor competitors. GPUs for artificial intelligence workloads come from a small number of manufacturers, and their availability and price can change quickly. U.S. export controls and sanctions could also restrict the customers to whom we may provide computing capacity, require us to implement customer screening procedures, and reduce the availability or increase the cost of GPU capacity from our suppliers. We will compete with hyperscale cloud providers and other GPU cloud and marketplace providers that have far greater resources and may offer lower prices or secure scarce supply first. GPU rental prices can fall quickly as supply grows or newer chips are released, and customers may move to hardware we do not offer (directly or indirectly). Because we expect to mainly resell capacity we buy from others, lower prices or higher costs would reduce our margins. Customers may reduce or end their use on short notice, and the loss of a few customers could materially reduce revenue and have a material and adverse impact on our business. Further, an outage at a data center or supplier, or a security incident affecting our platform or our suppliers, could interrupt service, lead to customer claims against us and materially and adversely impact our revenue and reputation.

 

38
 

 

Our rebranding, including our adoption of the GPU Exchange name and our new ticker symbol, may not be successful, and could confuse investors or harm our brand.

 

Effective at the open of trading on November 10, 2026, our common stock began trading on The Nasdaq Capital Market under the symbol “XGPU,” and we are now using “GPU Exchange” as a doing-business-as name, under which the Oblivus business we acquired on November 3, 2026 will operate. Our legal name remains Reliance Global Group, Inc., and we continue to operate our RELI Exchange InsurTech platform and our insurance brokerage business. This is our second ticker symbol change in 2026; our symbol changed from “RELI” to “EZRA” on January 26, 2026. We may not successfully establish the GPU Exchange name in the minds of customers, suppliers, investors or other market participants, and the use of a doing-business-as name that differs from our legal name, together with the repeated changes in our ticker symbol, could result in confusion, brand dilution or confusion about who we are and what we do. A name and ticker symbol focused on GPU computing may not reflect our insurance businesses, and we may spend more management time and financial resources promoting a brand that does not generate customer demand or investor interest. Any failure to successfully execute or communicate these changes could harm our reputation, our competitive position and the trading market for our common stock.

 

Expanding our GPU business to a Company-owned GPU fleet will require capital that may not be available on acceptable terms or at all.

 

We intend to invest in a Company-owned GPU fleet and in platform development, which will require capital beyond the cash we used to complete the acquisition. We may fund these investments through equity financings that would dilute existing stockholders or through debt financings that could result in material debt servicing commitments or subject us to restrictive covenants. The capital required may not be available on acceptable terms or at all. GPU hardware is expensive and can lose value quickly as newer chips are released. If we cannot fund our plans, we may not grow the business in the manner we planned, which could materially adversely affect our business and growth prospects.

 

Our stockholder rights plan and provisions of Florida law may discourage or delay a change of control.

 

On September 3, 2026, we entered into a one-year stockholder rights plan under which each outstanding share of our common stock carries one preferred stock purchase right (record date September 18, 2026). The rights generally become exercisable if a person or group acquires beneficial ownership of 15% or more of our common stock (20% for certain passive institutional investors) without approval of our Board, and expire on September 3, 2027 unless earlier redeemed, exchanged or terminated. The rights plan, together with provisions of Florida law and our articles of incorporation and bylaws, may discourage, delay or prevent a merger, tender offer or proxy contest that stockholders consider favorable and may limit the price investors are willing to pay for our common stock.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

During the three months ended September 30, 2026, the Company issued an aggregate of 24,916 shares of common stock, valued at approximately $60,000, to two investor relations service providers as compensation for services rendered. These securities were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, as transactions by an issuer not involving a public offering.

 

Item 3. Defaults Upon Senior Securities.

 

Not applicable.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

(a) None.

 

(b) There have been no material changes to the procedures by which security holders may recommend nominees to the Company’s Board of Directors since the Company last provided disclosure in response to the requirements of Item 407(c)(3) of Regulation S-K.

 

(c) During the quarter ended September 30, 2026, no director or officer adopted or terminated: (i) any contract, instruction or written plan for the purchase or sale of securities of the registrant intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (a “Rule 10b5-1 trading arrangement”); and/or (ii) any “non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K

 

39
 

 

Item 6. Exhibits

 

The following exhibits are filed or furnished with this Quarterly Report on Form 10-Q.

 

Exhibit No.   Description
     
2.1   Purchase and Contribution Agreement, dated to be effective as of September 1, 2026, by and among Southwestern Montana Insurance Center, LLC, Reliance Global Group, Inc. and Scali, LLC, dba Scali Insurance Group (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on September 9, 2026; certain schedules and exhibits omitted pursuant to Item 601(a)(5) of Regulation S-K).
     
2.2   Asset Purchase Agreement, dated as of September 23, 2026, by and among Altruis Benefit Consultants, Inc., Altruis Benefit Management, LLC and, solely for the purposes set forth therein, Reliance Global Group, Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on September 30, 2026; certain schedules and exhibits omitted pursuant to Item 601(a)(5) of Regulation S-K).
     
2.3   Closing Funding Letter Agreement, dated as of September 24, 2026, among Altruis Benefit Consultants, Inc., Altruis Benefit Management, LLC and Reliance Global Group, Inc. (incorporated by reference to Exhibit 2.2 to the Company’s Current Report on Form 8-K filed on September 30, 2026).
     
2.4   Asset Purchase Agreement, dated as of November 3, 2026, by and among GPU Exchange Corp., Skyportal Inc. and, solely for the limited purposes set forth therein, Matthew Antoun (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on November 9, 2026; certain schedules and exhibits omitted pursuant to Item 601(a)(5) of Regulation S-K; certain identified information has been excluded from this exhibit pursuant to Item 601(b)(2)(ii) of Regulation S-K).
     
3.1   Articles of Restatement to the Articles of Incorporation of Reliance Global Group, Inc. (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 17, 2026).
     
3.2   Amended and Restated Bylaws of Reliance Global Group, Inc., dated March 11, 2026 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 17, 2026).
     
3.3   Articles of Amendment to the Amended and Restated Articles of Incorporation of Reliance Global Group, Inc. (reverse stock split) (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on May 14, 2026).
     
3.4   Certificate of Designations of Series A Preferred Stock of Reliance Global Group, Inc., filed with the Florida Department of State on September 3, 2026 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on September 3, 2026).
     
4.1   Rights Agreement, dated as of September 3, 2026, between Reliance Global Group, Inc. and VStock Transfer, LLC, as rights agent (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed on September 3, 2026).
     
10.1   Common Stock Purchase Agreement, dated as of August 26, 2025, by and between Reliance Global Group, Inc. and White Lion Capital, LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on August 27, 2025).
     
10.2   Registration Rights Agreement, dated as of August 26, 2025, by and between Reliance Global Group, Inc. and White Lion Capital, LLC (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on August 27, 2025).
     
10.3   Interim Crypto Purchase Agreement, entered into between the Company and Moshe Fishman, dated September 16, 2025 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on September 19, 2025).
     
10.4   Amendment No. 1 to Common Stock Purchase Agreement, dated November 5, 2025, by and between Reliance Global Group, Inc. and White Lion Capital, LLC (incorporated by reference to Exhibit 10.7 to the Company’s Quarterly Report on Form 10-Q filed on November 6, 2025).
     
10.5   Amendment No. 2 to Common Stock Purchase Agreement, dated March 12, 2026, by and between Reliance Global Group, Inc. and White Lion Capital, LLC (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 17, 2026).
     
10.6   Full and Final Release and Settlement Agreement, dated March 13, 2026, by and among Reliance Global Group, Inc., Reliance Global Holdings, LLC, Ezra S. Beyman, Debbie Beyman, Eli Rubin and 9352-9113 Quebec Inc. d/b/a Excellent Photo (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 17, 2026).
     
10.7   Full and Final Release and Settlement Agreement, dated March 11, 2026, by and among Reliance Global Group, Inc., Reliance Global Holdings, LLC, Ezra S. Beyman, Debbie Beyman, Eliezer Kreindler and Lazar’s Group, Inc (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 17, 2026).
     
10.8   Promissory Note, dated April 29, 2026, by and between EZRA International Group LLC and LifeSci Global Group LLC (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on May 4, 2026).
     
10.9   Unit Subscription Agreement, dated April 30, 2026, by and between Innervate Radiopharmaceuticals LLC and LifeSci Global Group LLC (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on May 4, 2026).
     
10.10   Letter Agreement (Side Letter), dated April 30, 2026, by and between Innervate Radiopharmaceuticals LLC and LifeSci Global Group LLC (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on May 4, 2026).

 

40
 

 

10.11†   Reliance Global Group, Inc. 2025 Equity Incentive Plan (incorporated by reference to Appendix I to the Definitive Proxy Statement on Schedule 14A filed on April 15, 2025).
     
10.12†   Reliance Global Group, Inc. 2025 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 99.1 to the Registration Statement on Form S-8 (File No. 333-297136) filed with the Securities and Exchange Commission on June 29, 2026).
     
10.13   Share Purchase Agreement, dated February 5, 2026, by and between Reliance Global Group, Inc. and Enquantum Ltd. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 10, 2026).
     
10.14   Amendment No. 1 to Share Purchase Agreement, dated February 19, 2026, by and between Reliance Global Group, Inc. and Enquantum Ltd. (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 25, 2026).
     
10.15   Sixth Amendment to Master Credit Agreement and Credit Documents, dated as of September 4, 2026, by and among Oak Street Funding LLC, RELI Exchange, LLC, Altruis Benefit Consultants, Inc., Southwestern Montana Insurance Center, LLC and UIS Agency, LLC f/k/a Commercial Coverage Solutions LLC (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on September 11, 2026).
     
10.16   Reaffirmation of Credit Documents, dated as of September 4, 2026, by and between Reliance Global Group, Inc. and Oak Street Funding LLC (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on September 11, 2026).
     
10.17   Secured Promissory Note, dated September 24, 2026, made by Altruis Benefit Management, LLC and Trent D. Bryson in favor of Altruis Benefit Consultants, Inc. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on September 30, 2026; certain personally identifiable information redacted pursuant to Item 601(a)(6) of Regulation S-K).
     
10.18   Consulting Agreement, dated November 3, 2026, by and among GPU Exchange Corp., Reliance Global Group, Inc. (solely for purposes of Section 4(b)) and Matthew Antoun (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on November 9, 2026).
     
31.1*   Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
31.2*   Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1**   Section 1350 Certification of the Chief Executive Officer and Chief Financial Officer
     
101.INS*   Inline XBRL Instance Document
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*   Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (formatted in IXBRL, and included in exhibit 101).

 

*Filed herewith

**Furnished herewith

† Management contract, compensation plan or arrangement.

 

41
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  Reliance Global Group, Inc.
     
Date: November 16, 2026 By: /s/ Ezra Beyman
    Ezra Beyman
    Chief Executive Officer
    (principal executive officer)
     
Date: November 16, 2026 By: /s/ Joel Markovits
    Joel Markovits
    Chief Financial Officer
    (principal financial officer and principal accounting officer)

 

42